Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9542475,area under the concentration-time curve from time zero to 24 hours after the dose (AUC[0-24]),Rifampin decreased the area under the concentration-time curve from time zero to 24 hours after the dose (AUC[0-24]) of losartan by 35% (349 +/- 246 versus 225 +/- 130; p = 0.0001) and decreased the AUC(0-24) of E3174 by 40% (1336 +/- 445 versus 792 +/- 302; p < 0.005).,Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542475/),,349,8099,DB00678,Losartan
,9542475,area under the concentration-time curve from time zero to 24 hours after the dose (AUC[0-24]),Rifampin decreased the area under the concentration-time curve from time zero to 24 hours after the dose (AUC[0-24]) of losartan by 35% (349 +/- 246 versus 225 +/- 130; p = 0.0001) and decreased the AUC(0-24) of E3174 by 40% (1336 +/- 445 versus 792 +/- 302; p < 0.005).,Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542475/),,225,8100,DB00678,Losartan
,9542475,AUC(0-24),Rifampin decreased the area under the concentration-time curve from time zero to 24 hours after the dose (AUC[0-24]) of losartan by 35% (349 +/- 246 versus 225 +/- 130; p = 0.0001) and decreased the AUC(0-24) of E3174 by 40% (1336 +/- 445 versus 792 +/- 302; p < 0.005).,Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542475/),,1336,8101,DB00678,Losartan
,9542475,AUC(0-24),Rifampin decreased the area under the concentration-time curve from time zero to 24 hours after the dose (AUC[0-24]) of losartan by 35% (349 +/- 246 versus 225 +/- 130; p = 0.0001) and decreased the AUC(0-24) of E3174 by 40% (1336 +/- 445 versus 792 +/- 302; p < 0.005).,Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542475/),,792,8102,DB00678,Losartan
,12177688,time to reach the maximum plasma concentration (T(max)),The time to reach the maximum plasma concentration (T(max)) is 2.0 h for imidapril and 9.3 h for imidaprilat.,"Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177688/),h,2.0,8600,DB00678,Losartan
,12177688,time to reach the maximum plasma concentration (T(max)),The time to reach the maximum plasma concentration (T(max)) is 2.0 h for imidapril and 9.3 h for imidaprilat.,"Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177688/),h,9.3,8601,DB00678,Losartan
,12177688,elimination half-lives (t(1/2)),"The elimination half-lives (t(1/2)) of imidapril and imidaprilat is 1.7 and 14.8 h, respectively.","Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177688/),h,1.7,8602,DB00678,Losartan
,12177688,elimination half-lives (t(1/2)),"The elimination half-lives (t(1/2)) of imidapril and imidaprilat is 1.7 and 14.8 h, respectively.","Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177688/),h,14.8,8603,DB00678,Losartan
,8856481,Maximal inhibition,"Maximal inhibition of the systolic BP response was 54 +/- 3 (mean +/- SEM), 63 +/- 2, and 93 +/- 1% with 10, 40, and 80 mg LRB081, respectively.",Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),%,54,8991,DB00678,Losartan
,8856481,Maximal inhibition,"Maximal inhibition of the systolic BP response was 54 +/- 3 (mean +/- SEM), 63 +/- 2, and 93 +/- 1% with 10, 40, and 80 mg LRB081, respectively.",Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),%,63,8992,DB00678,Losartan
,8856481,Maximal inhibition,"Maximal inhibition of the systolic BP response was 54 +/- 3 (mean +/- SEM), 63 +/- 2, and 93 +/- 1% with 10, 40, and 80 mg LRB081, respectively.",Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),%,93,8993,DB00678,Losartan
,8856481,time to peak,The time to peak was 3 h for 6 subjects and 4 and 6 h for 2 others.,Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),h,3,8994,DB00678,Losartan
,8856481,time to peak,The time to peak was 3 h for 6 subjects and 4 and 6 h for 2 others.,Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),h,4,8995,DB00678,Losartan
,8856481,time to peak,The time to peak was 3 h for 6 subjects and 4 and 6 h for 2 others.,Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),h,6,8996,DB00678,Losartan
,8856481,plasma half-life (t1/2),Preliminary plasma half-life (t1/2) was calculated at 2 h.,Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),h,2,8997,DB00678,Losartan
,21666702,IC₅₀,"Ticlopidine inhibited CYP2C9 and 3A4 with IC₅₀ values of 26.0 and 32.3 μmol/L, respectively.",Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21666702/),[μM] / [l],26.0,13337,DB00678,Losartan
,21666702,IC₅₀,"Ticlopidine inhibited CYP2C9 and 3A4 with IC₅₀ values of 26.0 and 32.3 μmol/L, respectively.",Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21666702/),[μM] / [l],32.3,13338,DB00678,Losartan
,24380237,50% inhibition concentrations (IC50),"Licochalcon A inhibited CYP3A4 and CYP2C9 enzyme activities with 50% inhibition concentrations (IC50) of 2.0 and 0.1 microM, respectively.","Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24380237/),μM,2.0,14943,DB00678,Losartan
,24380237,50% inhibition concentrations (IC50),"Licochalcon A inhibited CYP3A4 and CYP2C9 enzyme activities with 50% inhibition concentrations (IC50) of 2.0 and 0.1 microM, respectively.","Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24380237/),μM,0.1,14944,DB00678,Losartan
longer,24132705,Tmax,"Meanwhile, the Cmax of amlodipine, losartan and EXP3174 were reduced by 11.4%, 20.0% and 41.4%, and the Tmax of losartan and EXP3174 were 1.3 and 1.8 h longer, respectively.",The influence of food on the pharmacokinetics of amlodipine and losartan after single-dose of its compound tablets in healthy chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24132705/),h,1.3,15630,DB00678,Losartan
longer,24132705,Tmax,"Meanwhile, the Cmax of amlodipine, losartan and EXP3174 were reduced by 11.4%, 20.0% and 41.4%, and the Tmax of losartan and EXP3174 were 1.3 and 1.8 h longer, respectively.",The influence of food on the pharmacokinetics of amlodipine and losartan after single-dose of its compound tablets in healthy chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24132705/),h,1.8,15631,DB00678,Losartan
,19750501,m/z,"The mass transition [M-H] ions used for detection were m/z 421.0 --> 127.0 for LOS, m/z 435.0 --> 157.0 for LA, and m/z 330.0 --> 239.0 for HFTZ.",Rapid determination of losartan and losartan acid in human plasma by multiplexed LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19750501/),,421.0,16428,DB00678,Losartan
,19750501,m/z,"The mass transition [M-H] ions used for detection were m/z 421.0 --> 127.0 for LOS, m/z 435.0 --> 157.0 for LA, and m/z 330.0 --> 239.0 for HFTZ.",Rapid determination of losartan and losartan acid in human plasma by multiplexed LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19750501/),,435.0,16429,DB00678,Losartan
,19750501,m/z,"The mass transition [M-H] ions used for detection were m/z 421.0 --> 127.0 for LOS, m/z 435.0 --> 157.0 for LA, and m/z 330.0 --> 239.0 for HFTZ.",Rapid determination of losartan and losartan acid in human plasma by multiplexed LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19750501/),,157.0,16430,DB00678,Losartan
,19750501,m/z,"The mass transition [M-H] ions used for detection were m/z 421.0 --> 127.0 for LOS, m/z 435.0 --> 157.0 for LA, and m/z 330.0 --> 239.0 for HFTZ.",Rapid determination of losartan and losartan acid in human plasma by multiplexed LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19750501/),,330.0,16431,DB00678,Losartan
,19750501,m/z,"The mass transition [M-H] ions used for detection were m/z 421.0 --> 127.0 for LOS, m/z 435.0 --> 157.0 for LA, and m/z 330.0 --> 239.0 for HFTZ.",Rapid determination of losartan and losartan acid in human plasma by multiplexed LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19750501/),,239.0,16432,DB00678,Losartan
,19750501,overall recoveries,"The overall recoveries for LOS, LA, and IS were 96.53, 99.86, and 94.16%, respectively.",Rapid determination of losartan and losartan acid in human plasma by multiplexed LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19750501/),%,96.53,16433,DB00678,Losartan
,19750501,overall recoveries,"The overall recoveries for LOS, LA, and IS were 96.53, 99.86, and 94.16%, respectively.",Rapid determination of losartan and losartan acid in human plasma by multiplexed LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19750501/),%,99.86,16434,DB00678,Losartan
,19750501,overall recoveries,"The overall recoveries for LOS, LA, and IS were 96.53, 99.86, and 94.16%, respectively.",Rapid determination of losartan and losartan acid in human plasma by multiplexed LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19750501/),%,94.16,16435,DB00678,Losartan
,19750501,Total MS run time,Total MS run time was 2.0 min/sample.,Rapid determination of losartan and losartan acid in human plasma by multiplexed LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19750501/),[min] / [sample],2.0,16436,DB00678,Losartan
,8138932,bioavailability,"The p.o. bioavailability of single doses of 5 to 20 mg/kg was low, 23 to 33%, and independent of the dose.",The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8138932/),%,23 to 33,23380,DB00678,Losartan
,8138932,elimination half-life,"The elimination half-life, 108 to 153 min, was longer than that observed after a single i.v. dose, 41 min, and may reflect both continuous absorption and enterohepatic recirculation because the major route of excretion was via the bile.",The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8138932/),min,108 to 153,23381,DB00678,Losartan
,8138932,elimination half-life,"The elimination half-life, 108 to 153 min, was longer than that observed after a single i.v. dose, 41 min, and may reflect both continuous absorption and enterohepatic recirculation because the major route of excretion was via the bile.",The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8138932/),min,41,23382,DB00678,Losartan
,8138932,systemic plasma clearance,"Single i.v. doses were eliminated rapidly, with a systemic plasma clearance of 22.2 ml/min/kg.",The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8138932/),[ml] / [kg·min],22.2,23383,DB00678,Losartan
,8138932,apparent volume of distribution at steady-state,Losartan was not distributed extensively to tissues; apparent volume of distribution at steady-state of 0.30 liters/kg and was highly but not extensively bound to plasma proteins; 2.7 to 2.9% unbound (free).,The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8138932/),[l] / [kg],0.30,23384,DB00678,Losartan
,8138932,IC50,"The relationship between concentration and effect was highly significant (r = 0.922, P < .01), with an IC50 (total) of 96 ng/ml.",The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8138932/),[ng] / [ml],96,23385,DB00678,Losartan
,25947361,total run time,"After solid-phase extraction, the analytes and internal standard (irbesartan) were extracted from 100 µL plasma sample on an Agilent Poroshell 120, EC-C18 (50 × 4.6 mm, i.d., 2.7 µm) column using 5 µL injection volume with a total run time of 3 min.","Simultaneous Determination and Pharmacokinetics of Metolazone, Losartan and Losartan Carboxylic Acid in Rat Plasma by HPLC-ESI-MS-MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25947361/),min,3,29789,DB00678,Losartan
,17220048,AUC0-infinity,"The AUC0-infinity of losartan was 2019.92+/-1002.90 and 2028.58+/-837.45 ng x h/ml for the test and reference formulation, respectively.",Bioequivalence study of two losartan formulations administered orally in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220048/),[h·ng] / [ml],2019.92,31798,DB00678,Losartan
,17220048,AUC0-infinity,"The AUC0-infinity of losartan was 2019.92+/-1002.90 and 2028.58+/-837.45 ng x h/ml for the test and reference formulation, respectively.",Bioequivalence study of two losartan formulations administered orally in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220048/),[h·ng] / [ml],2028.58,31799,DB00678,Losartan
,17220048,AUC0-infinity,"The AUC0-infinity of the metabolite was 10851.52+/-4438.66 and 11041.18 +/-5015.81 ng x h/ml for test and reference formulation, respectively.",Bioequivalence study of two losartan formulations administered orally in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220048/),[h·ng] / [ml],10851.52,31800,DB00678,Losartan
,17220048,AUC0-infinity,"The AUC0-infinity of the metabolite was 10851.52+/-4438.66 and 11041.18 +/-5015.81 ng x h/ml for test and reference formulation, respectively.",Bioequivalence study of two losartan formulations administered orally in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220048/),[h·ng] / [ml],11041.18,31801,DB00678,Losartan
,17220048,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) of losartan was 745.94+/-419.75 ng/ml for the test and 745.74+/-329.99 ng/ml for the reference product and the Cmax of the metabolite was 1805.77+/-765.39 and 1606.22 +/-977.22 ng/ml for the test and reference product, respectively.",Bioequivalence study of two losartan formulations administered orally in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220048/),[ng] / [ml],745.94,31802,DB00678,Losartan
,17220048,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) of losartan was 745.94+/-419.75 ng/ml for the test and 745.74+/-329.99 ng/ml for the reference product and the Cmax of the metabolite was 1805.77+/-765.39 and 1606.22 +/-977.22 ng/ml for the test and reference product, respectively.",Bioequivalence study of two losartan formulations administered orally in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220048/),[ng] / [ml],745.74,31803,DB00678,Losartan
,17220048,Cmax,"The maximum plasma concentration (Cmax) of losartan was 745.94+/-419.75 ng/ml for the test and 745.74+/-329.99 ng/ml for the reference product and the Cmax of the metabolite was 1805.77+/-765.39 and 1606.22 +/-977.22 ng/ml for the test and reference product, respectively.",Bioequivalence study of two losartan formulations administered orally in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220048/),[ng] / [ml],1805.77,31804,DB00678,Losartan
,17220048,Cmax,"The maximum plasma concentration (Cmax) of losartan was 745.94+/-419.75 ng/ml for the test and 745.74+/-329.99 ng/ml for the reference product and the Cmax of the metabolite was 1805.77+/-765.39 and 1606.22 +/-977.22 ng/ml for the test and reference product, respectively.",Bioequivalence study of two losartan formulations administered orally in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220048/),[ng] / [ml],1606.22,31805,DB00678,Losartan
,8703664,AUC(0.48h),"4. Multiple oral doses of losartan (50 mg daily) did not affect the pharmacokinetic parameters of 0.5 mg of digoxin i.v. AUC(0.48h) of immunoreactive digoxin during losartan 28.8 +/- 2.9 vs 28.5 +/- 3.9 ng ml-1 h during placebo; not significant, and 96 h urinary excretion [% dose] during losartan 54.0 +/- 7.2 vs 51.9 +/- 6.5% during placebo; not significant).",Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703664/),[h·ng] / [ml],28.8,35303,DB00678,Losartan
,8703664,AUC(0.48h),"4. Multiple oral doses of losartan (50 mg daily) did not affect the pharmacokinetic parameters of 0.5 mg of digoxin i.v. AUC(0.48h) of immunoreactive digoxin during losartan 28.8 +/- 2.9 vs 28.5 +/- 3.9 ng ml-1 h during placebo; not significant, and 96 h urinary excretion [% dose] during losartan 54.0 +/- 7.2 vs 51.9 +/- 6.5% during placebo; not significant).",Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703664/),[h·ng] / [ml],28.5,35304,DB00678,Losartan
,8703664,urinary excretion,"4. Multiple oral doses of losartan (50 mg daily) did not affect the pharmacokinetic parameters of 0.5 mg of digoxin i.v. AUC(0.48h) of immunoreactive digoxin during losartan 28.8 +/- 2.9 vs 28.5 +/- 3.9 ng ml-1 h during placebo; not significant, and 96 h urinary excretion [% dose] during losartan 54.0 +/- 7.2 vs 51.9 +/- 6.5% during placebo; not significant).",Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703664/),,96,35305,DB00678,Losartan
,8703664,urinary excretion,"4. Multiple oral doses of losartan (50 mg daily) did not affect the pharmacokinetic parameters of 0.5 mg of digoxin i.v. AUC(0.48h) of immunoreactive digoxin during losartan 28.8 +/- 2.9 vs 28.5 +/- 3.9 ng ml-1 h during placebo; not significant, and 96 h urinary excretion [% dose] during losartan 54.0 +/- 7.2 vs 51.9 +/- 6.5% during placebo; not significant).",Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703664/),%,54.0,35306,DB00678,Losartan
,8703664,urinary excretion,"4. Multiple oral doses of losartan (50 mg daily) did not affect the pharmacokinetic parameters of 0.5 mg of digoxin i.v. AUC(0.48h) of immunoreactive digoxin during losartan 28.8 +/- 2.9 vs 28.5 +/- 3.9 ng ml-1 h during placebo; not significant, and 96 h urinary excretion [% dose] during losartan 54.0 +/- 7.2 vs 51.9 +/- 6.5% during placebo; not significant).",Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703664/),%,51.9,35307,DB00678,Losartan
,8703664,AUC(0.48 h),"5. Multiple oral doses of losartan did not affect the pharmacokinetic parameters of oral digoxin AUC(0.48 h) during losartan 23.6 +/- 3.7 ng ml-1 h vs 22.4 +/- 2.6 ng ml-1 h during placebo; not significant, Cmax 3.5 +/- 0.7 ng ml-1 with vs 3.1 +/- 0.5 ng ml-1 without losartan; not significant and tmax 0.6 +/- 0.2 h with vs 0.9 +/- 0.7 h without losartan; not significant, and 96 h urinary excretion [% dose] during losartan 51.2 +/- 6.3 vs 46.3 +/- 2.4% during placebo; not significant).",Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703664/),[h·ng] / [ml],23.6,35308,DB00678,Losartan
,8703664,AUC(0.48 h),"5. Multiple oral doses of losartan did not affect the pharmacokinetic parameters of oral digoxin AUC(0.48 h) during losartan 23.6 +/- 3.7 ng ml-1 h vs 22.4 +/- 2.6 ng ml-1 h during placebo; not significant, Cmax 3.5 +/- 0.7 ng ml-1 with vs 3.1 +/- 0.5 ng ml-1 without losartan; not significant and tmax 0.6 +/- 0.2 h with vs 0.9 +/- 0.7 h without losartan; not significant, and 96 h urinary excretion [% dose] during losartan 51.2 +/- 6.3 vs 46.3 +/- 2.4% during placebo; not significant).",Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703664/),[h·ng] / [ml],22.4,35309,DB00678,Losartan
,8703664,Cmax,"5. Multiple oral doses of losartan did not affect the pharmacokinetic parameters of oral digoxin AUC(0.48 h) during losartan 23.6 +/- 3.7 ng ml-1 h vs 22.4 +/- 2.6 ng ml-1 h during placebo; not significant, Cmax 3.5 +/- 0.7 ng ml-1 with vs 3.1 +/- 0.5 ng ml-1 without losartan; not significant and tmax 0.6 +/- 0.2 h with vs 0.9 +/- 0.7 h without losartan; not significant, and 96 h urinary excretion [% dose] during losartan 51.2 +/- 6.3 vs 46.3 +/- 2.4% during placebo; not significant).",Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703664/),[ng] / [ml],3.5,35310,DB00678,Losartan
,8703664,Cmax,"5. Multiple oral doses of losartan did not affect the pharmacokinetic parameters of oral digoxin AUC(0.48 h) during losartan 23.6 +/- 3.7 ng ml-1 h vs 22.4 +/- 2.6 ng ml-1 h during placebo; not significant, Cmax 3.5 +/- 0.7 ng ml-1 with vs 3.1 +/- 0.5 ng ml-1 without losartan; not significant and tmax 0.6 +/- 0.2 h with vs 0.9 +/- 0.7 h without losartan; not significant, and 96 h urinary excretion [% dose] during losartan 51.2 +/- 6.3 vs 46.3 +/- 2.4% during placebo; not significant).",Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703664/),[ng] / [ml],3.1,35311,DB00678,Losartan
,8703664,tmax,"5. Multiple oral doses of losartan did not affect the pharmacokinetic parameters of oral digoxin AUC(0.48 h) during losartan 23.6 +/- 3.7 ng ml-1 h vs 22.4 +/- 2.6 ng ml-1 h during placebo; not significant, Cmax 3.5 +/- 0.7 ng ml-1 with vs 3.1 +/- 0.5 ng ml-1 without losartan; not significant and tmax 0.6 +/- 0.2 h with vs 0.9 +/- 0.7 h without losartan; not significant, and 96 h urinary excretion [% dose] during losartan 51.2 +/- 6.3 vs 46.3 +/- 2.4% during placebo; not significant).",Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703664/),h,0.6,35312,DB00678,Losartan
,8703664,tmax,"5. Multiple oral doses of losartan did not affect the pharmacokinetic parameters of oral digoxin AUC(0.48 h) during losartan 23.6 +/- 3.7 ng ml-1 h vs 22.4 +/- 2.6 ng ml-1 h during placebo; not significant, Cmax 3.5 +/- 0.7 ng ml-1 with vs 3.1 +/- 0.5 ng ml-1 without losartan; not significant and tmax 0.6 +/- 0.2 h with vs 0.9 +/- 0.7 h without losartan; not significant, and 96 h urinary excretion [% dose] during losartan 51.2 +/- 6.3 vs 46.3 +/- 2.4% during placebo; not significant).",Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703664/),h,0.9,35313,DB00678,Losartan
,8703664,urinary excretion,"5. Multiple oral doses of losartan did not affect the pharmacokinetic parameters of oral digoxin AUC(0.48 h) during losartan 23.6 +/- 3.7 ng ml-1 h vs 22.4 +/- 2.6 ng ml-1 h during placebo; not significant, Cmax 3.5 +/- 0.7 ng ml-1 with vs 3.1 +/- 0.5 ng ml-1 without losartan; not significant and tmax 0.6 +/- 0.2 h with vs 0.9 +/- 0.7 h without losartan; not significant, and 96 h urinary excretion [% dose] during losartan 51.2 +/- 6.3 vs 46.3 +/- 2.4% during placebo; not significant).",Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703664/),h,96,35314,DB00678,Losartan
,8703664,urinary excretion,"5. Multiple oral doses of losartan did not affect the pharmacokinetic parameters of oral digoxin AUC(0.48 h) during losartan 23.6 +/- 3.7 ng ml-1 h vs 22.4 +/- 2.6 ng ml-1 h during placebo; not significant, Cmax 3.5 +/- 0.7 ng ml-1 with vs 3.1 +/- 0.5 ng ml-1 without losartan; not significant and tmax 0.6 +/- 0.2 h with vs 0.9 +/- 0.7 h without losartan; not significant, and 96 h urinary excretion [% dose] during losartan 51.2 +/- 6.3 vs 46.3 +/- 2.4% during placebo; not significant).",Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703664/),%,51.2,35315,DB00678,Losartan
,8703664,urinary excretion,"5. Multiple oral doses of losartan did not affect the pharmacokinetic parameters of oral digoxin AUC(0.48 h) during losartan 23.6 +/- 3.7 ng ml-1 h vs 22.4 +/- 2.6 ng ml-1 h during placebo; not significant, Cmax 3.5 +/- 0.7 ng ml-1 with vs 3.1 +/- 0.5 ng ml-1 without losartan; not significant and tmax 0.6 +/- 0.2 h with vs 0.9 +/- 0.7 h without losartan; not significant, and 96 h urinary excretion [% dose] during losartan 51.2 +/- 6.3 vs 46.3 +/- 2.4% during placebo; not significant).",Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703664/),%,46.3,35316,DB00678,Losartan
higher,24890844,recovery,"Precision and accuracy values of the method were calculated as lower than 4.97% and ± 5.68, respectively and the recovery of LP from rabbit plasma was higher than 91.1%.",A new spectrofluorimetric method for determination of losartan potassium in rabbit plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24890844/),%,91.1,46522,DB00678,Losartan
,16294502,minimum detectable limit,The calibration curve was linear over the concentration range 5-300 ng mL(-1) with a minimum detectable limit of 2 ng mL(-1).,A rapid HPLC method for the determination of losartan in human plasma using a monolithic column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16294502/),[ng] / [ml],2,49528,DB00678,Losartan
,9821211,renal clearance (CLR),"However, the renal clearance (CLR) of losartan (0.181 versus 0.0815 ml/min/kg) and EXP3174 (0.0677 versus 0.0277 ml/min/kg) were significantly faster in SIDRs than in control rats due to significant increase in glomerular filtration rate.","Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821211/),[ml] / [kg·min],0.181,55363,DB00678,Losartan
,9821211,renal clearance (CLR),"However, the renal clearance (CLR) of losartan (0.181 versus 0.0815 ml/min/kg) and EXP3174 (0.0677 versus 0.0277 ml/min/kg) were significantly faster in SIDRs than in control rats due to significant increase in glomerular filtration rate.","Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821211/),[ml] / [kg·min],0.0815,55364,DB00678,Losartan
,9821211,renal clearance (CLR),"However, the renal clearance (CLR) of losartan (0.181 versus 0.0815 ml/min/kg) and EXP3174 (0.0677 versus 0.0277 ml/min/kg) were significantly faster in SIDRs than in control rats due to significant increase in glomerular filtration rate.","Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821211/),[ml] / [kg·min],0.0677,55365,DB00678,Losartan
,9821211,renal clearance (CLR),"However, the renal clearance (CLR) of losartan (0.181 versus 0.0815 ml/min/kg) and EXP3174 (0.0677 versus 0.0277 ml/min/kg) were significantly faster in SIDRs than in control rats due to significant increase in glomerular filtration rate.","Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821211/),[ml] / [kg·min],0.0277,55366,DB00678,Losartan
,9821211,arterial plasma concentrations,"After oral administration, the mean arterial plasma concentrations and the resultant AUC of losartan (97 versus 166 micrograms min/ml) and EXP3174 (244 versus 423 micrograms min/ml) were significantly lower in SIDRs than in control rats.","Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821211/),[min·μg] / [ml],97,55367,DB00678,Losartan
,9821211,arterial plasma concentrations,"After oral administration, the mean arterial plasma concentrations and the resultant AUC of losartan (97 versus 166 micrograms min/ml) and EXP3174 (244 versus 423 micrograms min/ml) were significantly lower in SIDRs than in control rats.","Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821211/),[min·μg] / [ml],166,55368,DB00678,Losartan
,9821211,AUC,"After oral administration, the mean arterial plasma concentrations and the resultant AUC of losartan (97 versus 166 micrograms min/ml) and EXP3174 (244 versus 423 micrograms min/ml) were significantly lower in SIDRs than in control rats.","Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821211/),[min·μg] / [ml],244,55369,DB00678,Losartan
,9821211,AUC,"After oral administration, the mean arterial plasma concentrations and the resultant AUC of losartan (97 versus 166 micrograms min/ml) and EXP3174 (244 versus 423 micrograms min/ml) were significantly lower in SIDRs than in control rats.","Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821211/),[min·μg] / [ml],423,55370,DB00678,Losartan
,9821211,oral bioavailability,"The absolute extent of oral bioavailability of losartan, F, (32.5 versus 55.1%) decreased considerably in SIDRs and it was possibly due to the reduced gastrointestinal absorption of losartan by gastrointestinal disorders occurring in the diabetic state.","Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821211/),%,32.5,55371,DB00678,Losartan
,9821211,oral bioavailability,"The absolute extent of oral bioavailability of losartan, F, (32.5 versus 55.1%) decreased considerably in SIDRs and it was possibly due to the reduced gastrointestinal absorption of losartan by gastrointestinal disorders occurring in the diabetic state.","Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821211/),%,55.1,55372,DB00678,Losartan
,9821211,CLR,The CLR of losartan (0.207 versus 0.101 ml/min/kg) and EXP3174 (0.0615 versus 0.0196 ml/min/kg) were significantly faster in SIDRs than in control rats after oral administration of losartan.,"Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821211/),[ml] / [kg·min],0.207,55373,DB00678,Losartan
,9821211,CLR,The CLR of losartan (0.207 versus 0.101 ml/min/kg) and EXP3174 (0.0615 versus 0.0196 ml/min/kg) were significantly faster in SIDRs than in control rats after oral administration of losartan.,"Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821211/),[ml] / [kg·min],0.101,55374,DB00678,Losartan
,9821211,CLR,The CLR of losartan (0.207 versus 0.101 ml/min/kg) and EXP3174 (0.0615 versus 0.0196 ml/min/kg) were significantly faster in SIDRs than in control rats after oral administration of losartan.,"Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821211/),[ml] / [kg·min],0.0615,55375,DB00678,Losartan
,9821211,CLR,The CLR of losartan (0.207 versus 0.101 ml/min/kg) and EXP3174 (0.0615 versus 0.0196 ml/min/kg) were significantly faster in SIDRs than in control rats after oral administration of losartan.,"Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821211/),[ml] / [kg·min],0.0196,55376,DB00678,Losartan
,8864166,AUC,"However, losartan and its active metabolite, EXP3174 (L-158,641) were readily detectable in fetal plasma on GD 20 (estimated AUC values, 50.70 and 167.70 micrograms/hr/ml, respectively) and maternal milk during lactation (1.61 and 1.67 micrograms/ml, respectively).",Toxicokinetic analysis of losartan during gestation and lactation in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864166/),[μg] / [h·ml],50.70,56838,DB00678,Losartan
,8864166,AUC,"However, losartan and its active metabolite, EXP3174 (L-158,641) were readily detectable in fetal plasma on GD 20 (estimated AUC values, 50.70 and 167.70 micrograms/hr/ml, respectively) and maternal milk during lactation (1.61 and 1.67 micrograms/ml, respectively).",Toxicokinetic analysis of losartan during gestation and lactation in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864166/),[μg] / [h·ml],167.70,56839,DB00678,Losartan
,8864166,AUC,"However, losartan and its active metabolite, EXP3174 (L-158,641) were readily detectable in fetal plasma on GD 20 (estimated AUC values, 50.70 and 167.70 micrograms/hr/ml, respectively) and maternal milk during lactation (1.61 and 1.67 micrograms/ml, respectively).",Toxicokinetic analysis of losartan during gestation and lactation in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864166/),[μg] / [ml],1.61,56840,DB00678,Losartan
,8864166,AUC,"However, losartan and its active metabolite, EXP3174 (L-158,641) were readily detectable in fetal plasma on GD 20 (estimated AUC values, 50.70 and 167.70 micrograms/hr/ml, respectively) and maternal milk during lactation (1.61 and 1.67 micrograms/ml, respectively).",Toxicokinetic analysis of losartan during gestation and lactation in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864166/),[μg] / [ml],1.67,56841,DB00678,Losartan
,8563699,IC50,"DMP 811 exhibited high binding affinity for the angiotensin II subtype receptor AT1 in rat adrenal tissues with an IC50 of 6 nM, but not for the subtype receptor AT2.",Pharmacology and pharmacokinetics of a novel nonpeptide angiotensin II receptor antagonist--DMP 811. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563699/),nM,6,57651,DB00678,Losartan
,8563699,KB,"In the isolated rabbit aorta, DMP 811 inhibited the contractile response to angiotensin II selectively and noncompetitively with a KB value of 0.1 nM.",Pharmacology and pharmacokinetics of a novel nonpeptide angiotensin II receptor antagonist--DMP 811. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563699/),nM,0.1,57652,DB00678,Losartan
,8563699,oral bioavailabilities,"DMP 811 has oral bioavailabilities of 7 and 29% in rats and dogs, respectively, after a solution dose and 8 and 13%, respectively, after a suspension or capsule dosing.",Pharmacology and pharmacokinetics of a novel nonpeptide angiotensin II receptor antagonist--DMP 811. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563699/),%,7,57653,DB00678,Losartan
,8563699,oral bioavailabilities,"DMP 811 has oral bioavailabilities of 7 and 29% in rats and dogs, respectively, after a solution dose and 8 and 13%, respectively, after a suspension or capsule dosing.",Pharmacology and pharmacokinetics of a novel nonpeptide angiotensin II receptor antagonist--DMP 811. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563699/),%,29,57654,DB00678,Losartan
,8563699,oral bioavailabilities,"DMP 811 has oral bioavailabilities of 7 and 29% in rats and dogs, respectively, after a solution dose and 8 and 13%, respectively, after a suspension or capsule dosing.",Pharmacology and pharmacokinetics of a novel nonpeptide angiotensin II receptor antagonist--DMP 811. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563699/),%,8,57655,DB00678,Losartan
,8563699,oral bioavailabilities,"DMP 811 has oral bioavailabilities of 7 and 29% in rats and dogs, respectively, after a solution dose and 8 and 13%, respectively, after a suspension or capsule dosing.",Pharmacology and pharmacokinetics of a novel nonpeptide angiotensin II receptor antagonist--DMP 811. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563699/),%,13,57656,DB00678,Losartan
,10761166,AUC0-24,"AUC0-24 and t1/2 for losartan and E-3174 were 95 +/- 49.9 micrograms.min/mL and 176 +/- 82.1 micrograms.min/mL and 172.5 +/- 86.7 minutes and 628 +/- 575 minutes, respectively.",The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761166/),[min·μg] / [ml],95,72570,DB00678,Losartan
,10761166,AUC0-24,"AUC0-24 and t1/2 for losartan and E-3174 were 95 +/- 49.9 micrograms.min/mL and 176 +/- 82.1 micrograms.min/mL and 172.5 +/- 86.7 minutes and 628 +/- 575 minutes, respectively.",The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761166/),min,172.5,72571,DB00678,Losartan
,10761166,t1/2,"AUC0-24 and t1/2 for losartan and E-3174 were 95 +/- 49.9 micrograms.min/mL and 176 +/- 82.1 micrograms.min/mL and 172.5 +/- 86.7 minutes and 628 +/- 575 minutes, respectively.",The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761166/),[min·μg] / [ml],176,72572,DB00678,Losartan
,10761166,t1/2,"AUC0-24 and t1/2 for losartan and E-3174 were 95 +/- 49.9 micrograms.min/mL and 176 +/- 82.1 micrograms.min/mL and 172.5 +/- 86.7 minutes and 628 +/- 575 minutes, respectively.",The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761166/),min,628,72573,DB00678,Losartan
,9518174,detection limit,"The method demonstrated linearity from 10 to 1000 ng/ml with a detection limit of 1 ng/ml for losartan and E-3174 using 10 microl of prepared plasma, urine or dialysate.","Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9518174/),[ng] / [ml],1,77358,DB00678,Losartan
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.95,81454,DB00678,Losartan
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.01,81455,DB00678,Losartan
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.97,81456,DB00678,Losartan
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.98,81457,DB00678,Losartan
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.36,81458,DB00678,Losartan
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.90,81459,DB00678,Losartan
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.79,81460,DB00678,Losartan
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.98,81461,DB00678,Losartan
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.66,81462,DB00678,Losartan
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.90,81463,DB00678,Losartan
,32272615,IC50 (Ki),"Of the nine tested CYPs, it exerted the strongest inhibitory effect on CYP2C9-mediated tolbutamide 4-hydroxylation with the lowest IC50 (Ki) value of 0.966 ± 0.149 μM (0.503 ± 0.0383 μM), in a competitive manner.",Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272615/),μM,0.966,82028,DB00678,Losartan
,32272615,IC50 (Ki),"Of the nine tested CYPs, it exerted the strongest inhibitory effect on CYP2C9-mediated tolbutamide 4-hydroxylation with the lowest IC50 (Ki) value of 0.966 ± 0.149 μM (0.503 ± 0.0383 μM), in a competitive manner.",Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272615/),μM,0.503,82029,DB00678,Losartan
,32272615,Papp,"The very low permeability of SPN in Caco-2 cells (Papp value of 0.115 × 10-6 cm/s), which suggests poor absorption in vivo, and its high degree of plasma protein binding (>99.9%) may lead to the lack of in vitro-in vivo correlation.",Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272615/),[cm] / [s],0.115 × 10-6,82030,DB00678,Losartan
>,32272615,plasma protein binding,"The very low permeability of SPN in Caco-2 cells (Papp value of 0.115 × 10-6 cm/s), which suggests poor absorption in vivo, and its high degree of plasma protein binding (>99.9%) may lead to the lack of in vitro-in vivo correlation.",Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272615/),%,99.9,82031,DB00678,Losartan
,27004954,IC50,From which compound 3 was found to be the most potent ligands with an IC50 value of 2.67±0.23 nM.,Synthesis and evaluation of novel angiotensin II receptor 1 antagonists as anti-hypertension drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004954/),nM,2.67,83037,DB00678,Losartan
,27004954,maximal response,"Biological evaluation in vivo revealed that all the compounds could cause significant decrease on MBP in a dose dependent manner in spontaneously hypertensive rats, and compound 3 especially showed an efficient and long-lasting effect in reducing blood pressure, whose maximal response lowered 41 mmHg of MBP at 10mg/kg and 62 mmHg at 15 mg/kg after oral administration, the significant anti-hypertensive effect lasted beyond 12 h, which is better than the reference compound losartan.",Synthesis and evaluation of novel angiotensin II receptor 1 antagonists as anti-hypertension drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004954/),mmhg,41,83038,DB00678,Losartan
,27004954,maximal response,"Biological evaluation in vivo revealed that all the compounds could cause significant decrease on MBP in a dose dependent manner in spontaneously hypertensive rats, and compound 3 especially showed an efficient and long-lasting effect in reducing blood pressure, whose maximal response lowered 41 mmHg of MBP at 10mg/kg and 62 mmHg at 15 mg/kg after oral administration, the significant anti-hypertensive effect lasted beyond 12 h, which is better than the reference compound losartan.",Synthesis and evaluation of novel angiotensin II receptor 1 antagonists as anti-hypertension drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004954/),mmhg,62,83039,DB00678,Losartan
,27004954,LD50,The acute toxicity assay suggested that it has low toxicity with the LD50 value of 2974.35 mg/kg.,Synthesis and evaluation of novel angiotensin II receptor 1 antagonists as anti-hypertension drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004954/),[mg] / [kg],2974.35,83040,DB00678,Losartan
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,27,85677,DB00678,Losartan
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,54,85678,DB00678,Losartan
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,44,85679,DB00678,Losartan
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,160,85680,DB00678,Losartan
,30916845,AUC0-6,"The geometric mean AUC0-6 (90% confidence interval) of melatonin, bupropion, repaglinide, chlorzoxazone and midazolam after LRYGB was 27 (19%-41%), 54 (43%-67%), 44 (29%-66%), 160 (129%-197%) and 74 (62%-90%) of the pre-surgery values, respectively.","Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30916845/),,74,85681,DB00678,Losartan
,31076412,K m,"ALS3 exhibited similar affinity in HIM and rCES2 with K m values of 6.92 and 6.77 μM, respectively, indicating that ALS3 is mainly hydrolyzed to Exp3174 in human intestine by CES2.","Carboxylesterase 2 and Intestine Transporters Contribute to the Low Bioavailability of Allisartan, a Prodrug of Exp3174 for Hypertension Treatment in Humans. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31076412/),μM,6.92,87414,DB00678,Losartan
,31076412,K m,"ALS3 exhibited similar affinity in HIM and rCES2 with K m values of 6.92 and 6.77 μM, respectively, indicating that ALS3 is mainly hydrolyzed to Exp3174 in human intestine by CES2.","Carboxylesterase 2 and Intestine Transporters Contribute to the Low Bioavailability of Allisartan, a Prodrug of Exp3174 for Hypertension Treatment in Humans. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31076412/),μM,6.77,87415,DB00678,Losartan
,31076412,K m,"Organic anion-transporting polypeptide 2B1 showed higher affinity and clearance toward ALS3 (K m 0.75 μM and intrinsic clearance 215 μl/min/mg) than those of Exp3174 (K m 7.85 μM and intrinsic clearance 16.1 μl/min/mg), indicating that ALS3 is preferred to be uptaken into intestinal epithelia.","Carboxylesterase 2 and Intestine Transporters Contribute to the Low Bioavailability of Allisartan, a Prodrug of Exp3174 for Hypertension Treatment in Humans. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31076412/),μM,0.75,87416,DB00678,Losartan
,31076412,intrinsic clearance,"Organic anion-transporting polypeptide 2B1 showed higher affinity and clearance toward ALS3 (K m 0.75 μM and intrinsic clearance 215 μl/min/mg) than those of Exp3174 (K m 7.85 μM and intrinsic clearance 16.1 μl/min/mg), indicating that ALS3 is preferred to be uptaken into intestinal epithelia.","Carboxylesterase 2 and Intestine Transporters Contribute to the Low Bioavailability of Allisartan, a Prodrug of Exp3174 for Hypertension Treatment in Humans. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31076412/),[μl] / [mg·min],215,87417,DB00678,Losartan
,31076412,K m,"Organic anion-transporting polypeptide 2B1 showed higher affinity and clearance toward ALS3 (K m 0.75 μM and intrinsic clearance 215 μl/min/mg) than those of Exp3174 (K m 7.85 μM and intrinsic clearance 16.1 μl/min/mg), indicating that ALS3 is preferred to be uptaken into intestinal epithelia.","Carboxylesterase 2 and Intestine Transporters Contribute to the Low Bioavailability of Allisartan, a Prodrug of Exp3174 for Hypertension Treatment in Humans. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31076412/),μM,7.85,87418,DB00678,Losartan
,31076412,intrinsic clearance,"Organic anion-transporting polypeptide 2B1 showed higher affinity and clearance toward ALS3 (K m 0.75 μM and intrinsic clearance 215 μl/min/mg) than those of Exp3174 (K m 7.85 μM and intrinsic clearance 16.1 μl/min/mg), indicating that ALS3 is preferred to be uptaken into intestinal epithelia.","Carboxylesterase 2 and Intestine Transporters Contribute to the Low Bioavailability of Allisartan, a Prodrug of Exp3174 for Hypertension Treatment in Humans. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31076412/),[μl] / [mg·min],16.1,87419,DB00678,Losartan
,26712820,"Kpu,u","Following that method, we determined that the value of ATV Kpu,u was 0.32, indicating that ATV hepatocellular clearance is uptake rate-limited.",Transport-Metabolism Interplay of Atazanavir in Rat Hepatocytes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26712820/),,0.32,100873,DB00678,Losartan
,16411525,CrCl,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),[l] / [·1.73·m2·week],51.3,101575,DB00678,Losartan
,16411525,CrCl,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),[l] / [·1.73·m2·week],45.8,101576,DB00678,Losartan
,16411525,Kt/V urea,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),,1.75,101577,DB00678,Losartan
,16411525,Kt/V urea,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),,1.59,101578,DB00678,Losartan
,16411525,drained dialysate volume,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),[l] / [d],8.80,101579,DB00678,Losartan
,16411525,drained dialysate volume,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),[l] / [d],8.44,101580,DB00678,Losartan
,12852442,absorption half-life,"The absorption half-life of the investigated drugs ranged from 2 to 59 min, and the extent of absorption from 21 to 94% in 2 h in the isolated perfused rat lung model.",Drug absorption from the isolated perfused rat lung--correlations with drug physicochemical properties and epithelial permeability. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852442/),min,2 to 59,102577,DB00678,Losartan
,9046346,IC50,"Compound 14n (3-tert-butyl-1-propyl-5-[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-y l] methyl]-1H-pyrazole-4-carboxylic acid, UR-7280) shows high potency both in vitro (IC50 = 3 nM) and in vivo (iv, 61.2 +/- 10% decrease in blood pressure at 0.3 mg/kg; po, 30 mmHg fall in blood pressure at 0.3 mg/kg), in comparison to losartan (IC50 = 59 nM; iv, 62.5 +/- 8.9% decrease in blood pressure at 1 mg/kg; po, 13 mmHg fall in blood pressure at 3 mg/kg).",Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9046346/),nM,3,114810,DB00678,Losartan
,9046346,IC50,"Compound 14n (3-tert-butyl-1-propyl-5-[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-y l] methyl]-1H-pyrazole-4-carboxylic acid, UR-7280) shows high potency both in vitro (IC50 = 3 nM) and in vivo (iv, 61.2 +/- 10% decrease in blood pressure at 0.3 mg/kg; po, 30 mmHg fall in blood pressure at 0.3 mg/kg), in comparison to losartan (IC50 = 59 nM; iv, 62.5 +/- 8.9% decrease in blood pressure at 1 mg/kg; po, 13 mmHg fall in blood pressure at 3 mg/kg).",Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9046346/),nM,59,114811,DB00678,Losartan
,31442620,AUC,"After exposure to EPP-AF®, it was observed decrease in the AUC0-∞ of fexofenadine, caffeine and losartan of approximately 18% (62.20 × 51.00 h.ng/mL), 8% (1085 × 999 h.ng/mL) and 13% (9.01 × 7.86 h.ng/mL), respectively, with all 90% CIs within the equivalence range of 0.80-1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),,62,116459,DB00678,Losartan
,31442620,AUC0-∞,"On the other hand, omeprazole and midazolam exhibited an increase in AUC0-∞ of, respectively, approximately 18% (18.90 × 22.30 h.ng/mL) and 14% (1.25 × 1.43 h.ng/mL), with the upper bounds of 90% CIs slightly above 1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),[h·ng] / [ml],18,116460,DB00678,Losartan
,31442620,AUC0-∞,"On the other hand, omeprazole and midazolam exhibited an increase in AUC0-∞ of, respectively, approximately 18% (18.90 × 22.30 h.ng/mL) and 14% (1.25 × 1.43 h.ng/mL), with the upper bounds of 90% CIs slightly above 1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),[h·ng] / [ml],1.,116461,DB00678,Losartan
,9740616,half-life (t1/2),"In vehicle-treated SD, SHR and TG+ the half-life (t1/2) of Ang-(1-7) averaged 10+/-1, 10+/-1, and 9+/-1 seconds, respectively.",Converting enzyme determines plasma clearance of angiotensin-(1-7). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9740616/),seconds,10,120673,DB00678,Losartan
,9740616,half-life (t1/2),"In vehicle-treated SD, SHR and TG+ the half-life (t1/2) of Ang-(1-7) averaged 10+/-1, 10+/-1, and 9+/-1 seconds, respectively.",Converting enzyme determines plasma clearance of angiotensin-(1-7). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9740616/),seconds,9,120674,DB00678,Losartan
,12235444,area under the concentration-time curve from time zero to 24 hours [AUC(0-24)],"Coadministration of phenytoin increased the mean area under the concentration-time curve from time zero to 24 hours [AUC(0-24)] of losartan by 17% (355 +/- 220 ng x h/mL versus 427 +/- 177 ng x h/mL; P =.1), but this difference was not statistically significant.",Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[h·ng] / [ml],355,124126,DB00678,Losartan
,12235444,area under the concentration-time curve from time zero to 24 hours [AUC(0-24)],"Coadministration of phenytoin increased the mean area under the concentration-time curve from time zero to 24 hours [AUC(0-24)] of losartan by 17% (355 +/- 220 ng x h/mL versus 427 +/- 177 ng x h/mL; P =.1), but this difference was not statistically significant.",Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[h·ng] / [ml],427,124127,DB00678,Losartan
,12235444,AUC(0-24),"In the 14 CYP2C9*1/*1 subjects, the mean AUC(0-24) of losartan was increased by 29% (284 +/- 84 ng x h/mL versus 402 +/- 128 ng x h/mL; P =.008).",Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[h·ng] / [ml],284,124128,DB00678,Losartan
,12235444,AUC(0-24),"In the 14 CYP2C9*1/*1 subjects, the mean AUC(0-24) of losartan was increased by 29% (284 +/- 84 ng x h/mL versus 402 +/- 128 ng x h/mL; P =.008).",Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[h·ng] / [ml],402,124129,DB00678,Losartan
,12235444,AUC(0-24),Coadministration of phenytoin significantly reduced the AUC(0-24) of E3174 by 63% (1254 +/- 256 ng x h/mL versus 466 +/- 174 ng x h/mL; P =.0001) and the formation clearance of losartan to E3174 (1.91 +/- 0.8 mL/h per kilogram versus 0.62 +/- 0.4 mL/h per kilogram; P =.0001).,Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[h·ng] / [ml],1254,124130,DB00678,Losartan
,12235444,AUC(0-24),Coadministration of phenytoin significantly reduced the AUC(0-24) of E3174 by 63% (1254 +/- 256 ng x h/mL versus 466 +/- 174 ng x h/mL; P =.0001) and the formation clearance of losartan to E3174 (1.91 +/- 0.8 mL/h per kilogram versus 0.62 +/- 0.4 mL/h per kilogram; P =.0001).,Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[h·ng] / [ml],466,124131,DB00678,Losartan
,12235444,formation clearance,Coadministration of phenytoin significantly reduced the AUC(0-24) of E3174 by 63% (1254 +/- 256 ng x h/mL versus 466 +/- 174 ng x h/mL; P =.0001) and the formation clearance of losartan to E3174 (1.91 +/- 0.8 mL/h per kilogram versus 0.62 +/- 0.4 mL/h per kilogram; P =.0001).,Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[ml] / [h·kg],1.91,124132,DB00678,Losartan
,12235444,formation clearance,Coadministration of phenytoin significantly reduced the AUC(0-24) of E3174 by 63% (1254 +/- 256 ng x h/mL versus 466 +/- 174 ng x h/mL; P =.0001) and the formation clearance of losartan to E3174 (1.91 +/- 0.8 mL/h per kilogram versus 0.62 +/- 0.4 mL/h per kilogram; P =.0001).,Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235444/),[ml] / [h·kg],0.62,124133,DB00678,Losartan
,28756559,flow rate,"Chromatographic separation was carried out using a Kinetex C18 column (100 × 4.6 mm; 100 Å; 2.6 μ) with acetonitrile/water with 0.2% (v/v) formic acid (65:35, v/v) in the isocratic mode at a flow rate of 0.4 mL/min.","Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756559/),[ml] / [min],0.4,131436,DB00678,Losartan
,28756559,mass transitions,"The mass transitions of LJ-2698 and IS were m/z 412.3 → 294.1 and m/z 423.1 → 207.2, respectively.","Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756559/),,412.3,131437,DB00678,Losartan
,28756559,mass transitions,"The mass transitions of LJ-2698 and IS were m/z 412.3 → 294.1 and m/z 423.1 → 207.2, respectively.","Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756559/),,294.1,131438,DB00678,Losartan
,28756559,mass transitions,"The mass transitions of LJ-2698 and IS were m/z 412.3 → 294.1 and m/z 423.1 → 207.2, respectively.","Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756559/),,423.1,131439,DB00678,Losartan
,28756559,mass transitions,"The mass transitions of LJ-2698 and IS were m/z 412.3 → 294.1 and m/z 423.1 → 207.2, respectively.","Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756559/),,207.2,131440,DB00678,Losartan
,28756559,m/,"The mass transitions of LJ-2698 and IS were m/z 412.3 → 294.1 and m/z 423.1 → 207.2, respectively.","Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756559/),,412.3,131441,DB00678,Losartan
,22784220,Peff,"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),[cm] / [s],0.16-44.16 × 10(-4),154149,DB00678,Losartan
,22784220,fraction unbound to plasma proteins (fu),"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.01-0.99,154150,DB00678,Losartan
,22784220,Saliva/plasma concentrations ratios,"Saliva/plasma concentrations ratios ranged 0.11-13.4, in agreement with drug protein binding and permeability.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.11-13.4,154151,DB00678,Losartan
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,28.0,156443,DB00678,Losartan
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,5.1,156444,DB00678,Losartan
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,9.9,156445,DB00678,Losartan
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,2.8,156446,DB00678,Losartan
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,22. 9,156447,DB00678,Losartan
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,14.7,156448,DB00678,Losartan
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,22.3,156449,DB00678,Losartan
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,11.1,156450,DB00678,Losartan
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,39.6,156451,DB00678,Losartan
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,26,156452,DB00678,Losartan
,31058419,AUCτ,"Losartan did not influence the exposure of amlodipine at steady-state (AUCτ , 165.15 ng h/mL [amlodipine alone] vs 172.36 ng h/mL [combination], P = 0.389) [geometric mean ratio (GMR) (90% confidence interval [CI]), 1.060 (0.954-1.178)].",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],165.15,156995,DB00678,Losartan
,31058419,AUCτ,"Losartan did not influence the exposure of amlodipine at steady-state (AUCτ , 165.15 ng h/mL [amlodipine alone] vs 172.36 ng h/mL [combination], P = 0.389) [geometric mean ratio (GMR) (90% confidence interval [CI]), 1.060 (0.954-1.178)].",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],172.36,156996,DB00678,Losartan
,31058419,AUCτ,"In addition, the exposure of EXP-3174 was not affected by amlodipine (AUCτ , 1159.46 ng h/mL vs 1105.10 ng h/mL, P = 0.295) (GMR [90% CI], 0.957 [0.891-1.027]).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],1159.46,156997,DB00678,Losartan
,31058419,AUCτ,"In addition, the exposure of EXP-3174 was not affected by amlodipine (AUCτ , 1159.46 ng h/mL vs 1105.10 ng h/mL, P = 0.295) (GMR [90% CI], 0.957 [0.891-1.027]).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],1105.10,156998,DB00678,Losartan
,31058419,AUCτ,"However, amlodipine significantly decreased the exposure of losartan at steady-state (AUCτ , 1241.50 ng h/mL vs 1082.02 ng h/mL, P = 0.006) (GMR [90% CI], 0.875 [0.813-0.942]) and increased oral clearance of losartan (84.65 L/h vs 97.26 L/h, P = 0.002).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],1241.50,156999,DB00678,Losartan
,31058419,AUCτ,"However, amlodipine significantly decreased the exposure of losartan at steady-state (AUCτ , 1241.50 ng h/mL vs 1082.02 ng h/mL, P = 0.006) (GMR [90% CI], 0.875 [0.813-0.942]) and increased oral clearance of losartan (84.65 L/h vs 97.26 L/h, P = 0.002).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[h·ng] / [ml],1082.02,157000,DB00678,Losartan
,31058419,oral clearance,"However, amlodipine significantly decreased the exposure of losartan at steady-state (AUCτ , 1241.50 ng h/mL vs 1082.02 ng h/mL, P = 0.006) (GMR [90% CI], 0.875 [0.813-0.942]) and increased oral clearance of losartan (84.65 L/h vs 97.26 L/h, P = 0.002).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[l] / [h],84.65,157001,DB00678,Losartan
,31058419,oral clearance,"However, amlodipine significantly decreased the exposure of losartan at steady-state (AUCτ , 1241.50 ng h/mL vs 1082.02 ng h/mL, P = 0.006) (GMR [90% CI], 0.875 [0.813-0.942]) and increased oral clearance of losartan (84.65 L/h vs 97.26 L/h, P = 0.002).",Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058419/),[l] / [h],97.26,157002,DB00678,Losartan
,8913542,terminal half-life,The terminal half-life of losartan ranged from 1.5 to 2.5 hours.,The clinical pharmacology of losartan in Japanese subjects and patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8913542/),h,1.5 to 2.5,163161,DB00678,Losartan
,8913542,bioavailability,"In other pharmacokinetic studies, it has been reported that bioavailability of losartan is about 33%, and its absorption is excellent.",The clinical pharmacology of losartan in Japanese subjects and patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8913542/),%,33,163162,DB00678,Losartan
,9438775,oral bioavailability,"Irbesartan has the highest oral bioavailability in its class (60% to 80%) and, unlike valsartan, its absorption is not affected by food.","The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438775/),%,60,165770,DB00678,Losartan
,9438775,oral bioavailability,"Irbesartan has the highest oral bioavailability in its class (60% to 80%) and, unlike valsartan, its absorption is not affected by food.","The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438775/),%,80,165771,DB00678,Losartan
,9438775,elimination half-life,"Irbesartan displays linear, dose related pharmacokinetics and, with the exception of tasosartan's active metabolite, has the longest elimination half-life of the AIIRA (11 to 15 h).","The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438775/),h,11 to 15,165772,DB00678,Losartan
,33509019,AUC(0-36),"Compared with individuals carrying the CYP2C9*1/*1 genotype, the CYP2C9*1/*3 genotype showed an increase in the AUC(0-36) (833.6 ± 379.8 ng h ml-1 vs. 526.1 ± 140.1 ng h ml-1, p < 0.05) and a decrease in the MR (the metabolic ratio of losartan, AUCE-3174/AUClosartan) (2.67 ± 1.40 vs. 4.56 ± 0.83, p < 0.05) of losartan during the placebo treatment phase.",Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33509019/),[h·ng] / [ml],833.6,168674,DB00678,Losartan
,33509019,AUC(0-36),"Compared with individuals carrying the CYP2C9*1/*1 genotype, the CYP2C9*1/*3 genotype showed an increase in the AUC(0-36) (833.6 ± 379.8 ng h ml-1 vs. 526.1 ± 140.1 ng h ml-1, p < 0.05) and a decrease in the MR (the metabolic ratio of losartan, AUCE-3174/AUClosartan) (2.67 ± 1.40 vs. 4.56 ± 0.83, p < 0.05) of losartan during the placebo treatment phase.",Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33509019/),[h·ng] / [ml],526.1,168675,DB00678,Losartan
,33509019,AUC(0-36),"Individuals with genotype CYP2C9*1/*3 showed a significant increase in AUC(0-36) (2335 ± 851.8 ng h ml-1 vs. 1927 ± 949.5 ng h ml-1, p < 0.05) and AUC(0-∞) (2363 ± 875.6 ng h ml-1 vs. 1966 ± 966.1 ng h ml-1, p < 0.05) of E-3174 after breviscapine treatment compared to the placebo group.",Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33509019/),[h·ng] / [ml],2335,168676,DB00678,Losartan
,33509019,AUC(0-36),"Individuals with genotype CYP2C9*1/*3 showed a significant increase in AUC(0-36) (2335 ± 851.8 ng h ml-1 vs. 1927 ± 949.5 ng h ml-1, p < 0.05) and AUC(0-∞) (2363 ± 875.6 ng h ml-1 vs. 1966 ± 966.1 ng h ml-1, p < 0.05) of E-3174 after breviscapine treatment compared to the placebo group.",Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33509019/),[h·ng] / [ml],1927,168677,DB00678,Losartan
,33509019,AUC(0-∞),"Individuals with genotype CYP2C9*1/*3 showed a significant increase in AUC(0-36) (2335 ± 851.8 ng h ml-1 vs. 1927 ± 949.5 ng h ml-1, p < 0.05) and AUC(0-∞) (2363 ± 875.6 ng h ml-1 vs. 1966 ± 966.1 ng h ml-1, p < 0.05) of E-3174 after breviscapine treatment compared to the placebo group.",Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33509019/),[h·ng] / [ml],2363,168678,DB00678,Losartan
,33509019,AUC(0-∞),"Individuals with genotype CYP2C9*1/*3 showed a significant increase in AUC(0-36) (2335 ± 851.8 ng h ml-1 vs. 1927 ± 949.5 ng h ml-1, p < 0.05) and AUC(0-∞) (2363 ± 875.6 ng h ml-1 vs. 1966 ± 966.1 ng h ml-1, p < 0.05) of E-3174 after breviscapine treatment compared to the placebo group.",Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33509019/),[h·ng] / [ml],1966,168679,DB00678,Losartan
,21709429,IC₅₀,"Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709429/),[μM] / [l],48.0,169350,DB00678,Losartan
,21709429,IC₅₀,"Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709429/),[μM] / [l],14.1,169351,DB00678,Losartan
,21709429,IC₅₀,"Atorvastatin, pravastatin and simvastatin inhibited CYP3A4 activities with IC₅₀ values of 48.0, 14.1 and 3.10 μmol/l, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709429/),[μM] / [l],3.10,169352,DB00678,Losartan
,11011981,flow rate,The system was operated isocratically at ambient temperature at a flow rate of 0.3 ml/min.,Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011981/),[ml] / [min],0.3,173667,DB00678,Losartan
greater,11011981,recoveries,recoveries of losartan and EXP3174 from plasma were greater than 70%.,Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011981/),%,70,173668,DB00678,Losartan
<,11011981,Sensitivity,Sensitivity of the assay was < 10 ng/ml.,Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011981/),ng,10,173669,DB00678,Losartan
,15274676,plasma levels,"Mean bradykinin plasma levels peaked in the efferent line post-adsorber at 1000 mL of treated blood volume; 467 fmol/mL (N = 6 sessions) in the ARA-treated patients and 671 fmol/mL (N = 9 sessions) in a control group of three DALI patients without ARA medication (P = 0.69, n.s.).",Efficacy and safety of DALI-LDL-apheresis in two patients treated with the angiotensin II-receptor 1 antagonist losartan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15274676/),[fmol] / [ml],467,174332,DB00678,Losartan
,15274676,plasma levels,"Mean bradykinin plasma levels peaked in the efferent line post-adsorber at 1000 mL of treated blood volume; 467 fmol/mL (N = 6 sessions) in the ARA-treated patients and 671 fmol/mL (N = 9 sessions) in a control group of three DALI patients without ARA medication (P = 0.69, n.s.).",Efficacy and safety of DALI-LDL-apheresis in two patients treated with the angiotensin II-receptor 1 antagonist losartan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15274676/),[fmol] / [ml],671,174333,DB00678,Losartan
,19277953,flow-rate,"An isocratic mobile phase, acetonitrile:0.1% formic acid (37:63, v/v), was run at a flow-rate of 1.0 mL/min, and the column eluent was monitored using a fluorescence detector set at excitation and emission wavelengths of 250 and 370 nm, respectively.",HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277953/),[ml] / [min],1.0,180383,DB00678,Losartan
,19277953,retention times,"The retention times of irbesartan and losartan were 4.4 and 5.9 min, respectively.",HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277953/),min,4.4,180384,DB00678,Losartan
,19277953,retention times,"The retention times of irbesartan and losartan were 4.4 and 5.9 min, respectively.",HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277953/),min,5.9,180385,DB00678,Losartan
,19277953,relative recoveries,"The mean relative recoveries of irbesartan and losartan were 98.4 and 99.1%, respectively.",HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277953/),%,98.4,180386,DB00678,Losartan
,19277953,relative recoveries,"The mean relative recoveries of irbesartan and losartan were 98.4 and 99.1%, respectively.",HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277953/),%,99.1,180387,DB00678,Losartan
,29953302,Cmax,"The Cmax (1.22 ± 0.25 vs 1.85 ± 0.37 μg/mL) and the AUC(0-t) (6.99 ± 1.05 vs 11.94 ± 1.79 mg·h/L) of losartan increased significantly (p < 0.05) with GLT pretreatment, while the Cmax (1.05 ± 0.19 vs 0.72 ± 0.12 μg/mL) of EXP3174 decreased significantly (p < 0.05) compared to the control.",Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),[μg] / [ml],1.22,180464,DB00678,Losartan
,29953302,Cmax,"The Cmax (1.22 ± 0.25 vs 1.85 ± 0.37 μg/mL) and the AUC(0-t) (6.99 ± 1.05 vs 11.94 ± 1.79 mg·h/L) of losartan increased significantly (p < 0.05) with GLT pretreatment, while the Cmax (1.05 ± 0.19 vs 0.72 ± 0.12 μg/mL) of EXP3174 decreased significantly (p < 0.05) compared to the control.",Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),[μg] / [ml],1.85,180465,DB00678,Losartan
,29953302,AUC(0-t),"The Cmax (1.22 ± 0.25 vs 1.85 ± 0.37 μg/mL) and the AUC(0-t) (6.99 ± 1.05 vs 11.94 ± 1.79 mg·h/L) of losartan increased significantly (p < 0.05) with GLT pretreatment, while the Cmax (1.05 ± 0.19 vs 0.72 ± 0.12 μg/mL) of EXP3174 decreased significantly (p < 0.05) compared to the control.",Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),[h·mg] / [l],6.99,180466,DB00678,Losartan
,29953302,AUC(0-t),"The Cmax (1.22 ± 0.25 vs 1.85 ± 0.37 μg/mL) and the AUC(0-t) (6.99 ± 1.05 vs 11.94 ± 1.79 mg·h/L) of losartan increased significantly (p < 0.05) with GLT pretreatment, while the Cmax (1.05 ± 0.19 vs 0.72 ± 0.12 μg/mL) of EXP3174 decreased significantly (p < 0.05) compared to the control.",Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),[h·mg] / [l],11.94,180467,DB00678,Losartan
,29953302,Cmax,"The Cmax (1.22 ± 0.25 vs 1.85 ± 0.37 μg/mL) and the AUC(0-t) (6.99 ± 1.05 vs 11.94 ± 1.79 mg·h/L) of losartan increased significantly (p < 0.05) with GLT pretreatment, while the Cmax (1.05 ± 0.19 vs 0.72 ± 0.12 μg/mL) of EXP3174 decreased significantly (p < 0.05) compared to the control.",Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),[μg] / [ml],1.05,180468,DB00678,Losartan
,29953302,Cmax,"The Cmax (1.22 ± 0.25 vs 1.85 ± 0.37 μg/mL) and the AUC(0-t) (6.99 ± 1.05 vs 11.94 ± 1.79 mg·h/L) of losartan increased significantly (p < 0.05) with GLT pretreatment, while the Cmax (1.05 ± 0.19 vs 0.72 ± 0.12 μg/mL) of EXP3174 decreased significantly (p < 0.05) compared to the control.",Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),[μg] / [ml],0.72,180469,DB00678,Losartan
,29953302,t1/2,The t1/2 of losartan was prolonged significantly from 3.94 ± 0.62 to 4.75 ± 0.52 h (p < 0.05).,Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),h,3.94,180470,DB00678,Losartan
,29953302,t1/2,The t1/2 of losartan was prolonged significantly from 3.94 ± 0.62 to 4.75 ± 0.52 h (p < 0.05).,Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),h,4.75,180471,DB00678,Losartan
,29953302,metabolic stability,The metabolic stability of losartan was increased from 37.4 min to 59.6 min with GLT pretreatment.,Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),min,37.4,180472,DB00678,Losartan
,29953302,metabolic stability,The metabolic stability of losartan was increased from 37.4 min to 59.6 min with GLT pretreatment.,Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29953302/),min,59.6,180473,DB00678,Losartan
,32294941,flow rate,"The mobile phase, comprising 10 mM ammonium formate in water pH 5.75) and acetonitrile (11:89, v/v), was eluted at a flow rate of 0.4 mL/min.","Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Pharmacokinetic Evaluation of 7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranon in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32294941/),[ml] / [min],0.4,181149,DB00678,Losartan
,32294941,mass,"Mass spectrometric detection was performed in the multiple reaction monitoring mode with positive electrospray ionization, and the mass transitions of ECN and LST were m/z 431.3 to 97.3 and m/z 423.1 to 207.2, respectively.","Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Pharmacokinetic Evaluation of 7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranon in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32294941/),,431.3,181150,DB00678,Losartan
,32294941,m/,"Mass spectrometric detection was performed in the multiple reaction monitoring mode with positive electrospray ionization, and the mass transitions of ECN and LST were m/z 431.3 to 97.3 and m/z 423.1 to 207.2, respectively.","Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Pharmacokinetic Evaluation of 7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranon in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32294941/),,431.3,181151,DB00678,Losartan
,32294941,m/,"Mass spectrometric detection was performed in the multiple reaction monitoring mode with positive electrospray ionization, and the mass transitions of ECN and LST were m/z 431.3 to 97.3 and m/z 423.1 to 207.2, respectively.","Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Pharmacokinetic Evaluation of 7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranon in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32294941/),,97,181152,DB00678,Losartan
,32294941,m/,"Mass spectrometric detection was performed in the multiple reaction monitoring mode with positive electrospray ionization, and the mass transitions of ECN and LST were m/z 431.3 to 97.3 and m/z 423.1 to 207.2, respectively.","Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Pharmacokinetic Evaluation of 7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranon in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32294941/),,423.1,181153,DB00678,Losartan
,32294941,m/,"Mass spectrometric detection was performed in the multiple reaction monitoring mode with positive electrospray ionization, and the mass transitions of ECN and LST were m/z 431.3 to 97.3 and m/z 423.1 to 207.2, respectively.","Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Pharmacokinetic Evaluation of 7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranon in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32294941/),,207.2,181154,DB00678,Losartan
,26839805,flow rate,"After solid phase extraction (SPE), analytes and ISs were separated on an Agilent Poroshell 120, EC-C18 (50 mm × 4.6 mm, i.d., 2.7 μm) column with a mobile phase consisting of methanol/water (85:15, v/v) containing 5 mmol/L ammonium formate and 0.1% formic acid at a flow rate of 0.4 mL/min.","Simultaneous Determination and Pharmacokinetic Study of Losartan, Losartan Carboxylic Acid, Ramipril, Ramiprilat, and Hydrochlorothiazide in Rat Plasma by a Liquid Chromatography/Tandem Mass Spectrometry Method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26839805/),[ml] / [min],0.4,182648,DB00678,Losartan
,20678685,relative bioavailability,The relative bioavailability of the test formulation to the reference formulation was 93.92% for losartan and 100.40% for EXP3174.,"Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678685/),%,93.92,185399,DB00678,Losartan
,20678685,relative bioavailability,The relative bioavailability of the test formulation to the reference formulation was 93.92% for losartan and 100.40% for EXP3174.,"Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678685/),%,100.40,185400,DB00678,Losartan
,18307734,bioavailability,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),%,2.6 and 5.0,185713,DB00678,Losartan
,18307734,IC50,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),[nM] / [l],0.6,185714,DB00678,Losartan
,18307734,plasma half-life,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),h,23-36,185715,DB00678,Losartan
,31511782,half-life (t 1/2),The half-life (t 1/2) of losartan was decreased by Xuesaitong (4.26 ± 1.51 vs. 6.35 ± 2.10 h; P < 0.05).,Effects of Xuesaitong on the Pharmacokinetics of Losartan: An In Vivo UPLC-MS/MS Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511782/),h,4.26,185834,DB00678,Losartan
,31511782,half-life (t 1/2),The half-life (t 1/2) of losartan was decreased by Xuesaitong (4.26 ± 1.51 vs. 6.35 ± 2.10 h; P < 0.05).,Effects of Xuesaitong on the Pharmacokinetics of Losartan: An In Vivo UPLC-MS/MS Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511782/),h,6.35,185835,DB00678,Losartan
,31511782,apparent volume of distribution (V d),The apparent volume of distribution (V d) of losartan was also decreased by the combination of losartan and Xuesaitong (4.41 ± 1.61 vs. 7.20 ± 2.41 mL; P < 0.05).,Effects of Xuesaitong on the Pharmacokinetics of Losartan: An In Vivo UPLC-MS/MS Study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511782/),ml,4.41,185836,DB00678,Losartan
,31511782,apparent volume of distribution (V d),The apparent volume of distribution (V d) of losartan was also decreased by the combination of losartan and Xuesaitong (4.41 ± 1.61 vs. 7.20 ± 2.41 mL; P < 0.05).,Effects of Xuesaitong on the Pharmacokinetics of Losartan: An In Vivo UPLC-MS/MS Study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511782/),ml,7.20,185837,DB00678,Losartan
,31511782,time to maximum concentration (T max),The time to maximum concentration (T max) of losartan was increased by Xuesaitong (1.06 ± 1.04 vs. 0.13 ± 0.05 h; P < 0.05).,Effects of Xuesaitong on the Pharmacokinetics of Losartan: An In Vivo UPLC-MS/MS Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511782/),h,1.06,185838,DB00678,Losartan
,31511782,time to maximum concentration (T max),The time to maximum concentration (T max) of losartan was increased by Xuesaitong (1.06 ± 1.04 vs. 0.13 ± 0.05 h; P < 0.05).,Effects of Xuesaitong on the Pharmacokinetics of Losartan: An In Vivo UPLC-MS/MS Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511782/),h,0.13,185839,DB00678,Losartan
,31511782,t 1/2,Xuesaitong also decreased the t 1/2 of EXP3174 (8.22 ± 1.41 vs. 6.29 ± 1.38 h; P < 0.05).,Effects of Xuesaitong on the Pharmacokinetics of Losartan: An In Vivo UPLC-MS/MS Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511782/),h,8.22,185840,DB00678,Losartan
,31511782,t 1/2,Xuesaitong also decreased the t 1/2 of EXP3174 (8.22 ± 1.41 vs. 6.29 ± 1.38 h; P < 0.05).,Effects of Xuesaitong on the Pharmacokinetics of Losartan: An In Vivo UPLC-MS/MS Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31511782/),h,6.29,185841,DB00678,Losartan
,30668856,m/z,Molecular masses of daughter species of losartan were m/z 423.19 > 207 and m/z 423.19 > 180; and of eprosartan were m/z 425.11 > 135 and m/z 425.11 > 107.,A Validated Ultra-Performance Liquid Chromatography Tandem Triple Quadrupole Mass Spectrometric Method for Fast Determination of Losartan in Rabbit Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30668856/),,425.11,187932,DB00678,Losartan
>,30668856,m/z,Molecular masses of daughter species of losartan were m/z 423.19 > 207 and m/z 423.19 > 180; and of eprosartan were m/z 425.11 > 135 and m/z 425.11 > 107.,A Validated Ultra-Performance Liquid Chromatography Tandem Triple Quadrupole Mass Spectrometric Method for Fast Determination of Losartan in Rabbit Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30668856/),,135,187933,DB00678,Losartan
>,30668856,m/z,Molecular masses of daughter species of losartan were m/z 423.19 > 207 and m/z 423.19 > 180; and of eprosartan were m/z 425.11 > 135 and m/z 425.11 > 107.,A Validated Ultra-Performance Liquid Chromatography Tandem Triple Quadrupole Mass Spectrometric Method for Fast Determination of Losartan in Rabbit Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30668856/),,425.11,187934,DB00678,Losartan
>,30668856,m/z,Molecular masses of daughter species of losartan were m/z 423.19 > 207 and m/z 423.19 > 180; and of eprosartan were m/z 425.11 > 135 and m/z 425.11 > 107.,A Validated Ultra-Performance Liquid Chromatography Tandem Triple Quadrupole Mass Spectrometric Method for Fast Determination of Losartan in Rabbit Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30668856/),,107,187935,DB00678,Losartan
,30668856,Sample run time,Sample run time was 3.0 min.,A Validated Ultra-Performance Liquid Chromatography Tandem Triple Quadrupole Mass Spectrometric Method for Fast Determination of Losartan in Rabbit Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30668856/),min,3.0,187936,DB00678,Losartan
,30668856,Cmax,"Pharmacokinetic parameters such as Cmax (182.79 ± 23.80 ng/mL), Tmax (1.16 ± 0.28 h), AUC0-t (1188.57 ± 404.60 ng h/mL) and Kel (0.0954 ± 0.0140 h-1) of losartan were measured.",A Validated Ultra-Performance Liquid Chromatography Tandem Triple Quadrupole Mass Spectrometric Method for Fast Determination of Losartan in Rabbit Plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30668856/),[ng] / [ml],182.79,187937,DB00678,Losartan
,30668856,Tmax,"Pharmacokinetic parameters such as Cmax (182.79 ± 23.80 ng/mL), Tmax (1.16 ± 0.28 h), AUC0-t (1188.57 ± 404.60 ng h/mL) and Kel (0.0954 ± 0.0140 h-1) of losartan were measured.",A Validated Ultra-Performance Liquid Chromatography Tandem Triple Quadrupole Mass Spectrometric Method for Fast Determination of Losartan in Rabbit Plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30668856/),h,1.16,187938,DB00678,Losartan
,30668856,AUC0-t,"Pharmacokinetic parameters such as Cmax (182.79 ± 23.80 ng/mL), Tmax (1.16 ± 0.28 h), AUC0-t (1188.57 ± 404.60 ng h/mL) and Kel (0.0954 ± 0.0140 h-1) of losartan were measured.",A Validated Ultra-Performance Liquid Chromatography Tandem Triple Quadrupole Mass Spectrometric Method for Fast Determination of Losartan in Rabbit Plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30668856/),[h·ng] / [ml],1188.57,187939,DB00678,Losartan
,30668856,Kel,"Pharmacokinetic parameters such as Cmax (182.79 ± 23.80 ng/mL), Tmax (1.16 ± 0.28 h), AUC0-t (1188.57 ± 404.60 ng h/mL) and Kel (0.0954 ± 0.0140 h-1) of losartan were measured.",A Validated Ultra-Performance Liquid Chromatography Tandem Triple Quadrupole Mass Spectrometric Method for Fast Determination of Losartan in Rabbit Plasma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30668856/),1/[h],0.0954,187940,DB00678,Losartan
,27327872,Cmax,"The Cmax (1.26 ± 0.37 versus 1.96 ± 0.45 mg/L) and the AUC(0-t) (8.25 ± 0.89 versus 12.70 ± 1.42 mg h/L) of losartan were significantly (p < 0.05) increased by BBR compared to the control, while the Cmax (0.97 ± 0.15 versus 0.77 ± 0.06 mg/L) of EXP3174 was significantly decreased compared to the control (p < 0.05).",Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27327872/),[mg] / [l],1.26,188489,DB00678,Losartan
,27327872,Cmax,"The Cmax (1.26 ± 0.37 versus 1.96 ± 0.45 mg/L) and the AUC(0-t) (8.25 ± 0.89 versus 12.70 ± 1.42 mg h/L) of losartan were significantly (p < 0.05) increased by BBR compared to the control, while the Cmax (0.97 ± 0.15 versus 0.77 ± 0.06 mg/L) of EXP3174 was significantly decreased compared to the control (p < 0.05).",Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27327872/),[mg] / [l],1.96,188490,DB00678,Losartan
,27327872,AUC(0-t),"The Cmax (1.26 ± 0.37 versus 1.96 ± 0.45 mg/L) and the AUC(0-t) (8.25 ± 0.89 versus 12.70 ± 1.42 mg h/L) of losartan were significantly (p < 0.05) increased by BBR compared to the control, while the Cmax (0.97 ± 0.15 versus 0.77 ± 0.06 mg/L) of EXP3174 was significantly decreased compared to the control (p < 0.05).",Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27327872/),[h·mg] / [l],8.25,188491,DB00678,Losartan
,27327872,AUC(0-t),"The Cmax (1.26 ± 0.37 versus 1.96 ± 0.45 mg/L) and the AUC(0-t) (8.25 ± 0.89 versus 12.70 ± 1.42 mg h/L) of losartan were significantly (p < 0.05) increased by BBR compared to the control, while the Cmax (0.97 ± 0.15 versus 0.77 ± 0.06 mg/L) of EXP3174 was significantly decreased compared to the control (p < 0.05).",Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27327872/),[h·mg] / [l],12.70,188492,DB00678,Losartan
,27327872,Cmax,"The Cmax (1.26 ± 0.37 versus 1.96 ± 0.45 mg/L) and the AUC(0-t) (8.25 ± 0.89 versus 12.70 ± 1.42 mg h/L) of losartan were significantly (p < 0.05) increased by BBR compared to the control, while the Cmax (0.97 ± 0.15 versus 0.77 ± 0.06 mg/L) of EXP3174 was significantly decreased compared to the control (p < 0.05).",Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27327872/),[mg] / [l],0.97,188493,DB00678,Losartan
,27327872,Cmax,"The Cmax (1.26 ± 0.37 versus 1.96 ± 0.45 mg/L) and the AUC(0-t) (8.25 ± 0.89 versus 12.70 ± 1.42 mg h/L) of losartan were significantly (p < 0.05) increased by BBR compared to the control, while the Cmax (0.97 ± 0.15 versus 0.77 ± 0.06 mg/L) of EXP3174 was significantly decreased compared to the control (p < 0.05).",Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27327872/),[mg] / [l],0.77,188494,DB00678,Losartan
,27327872,Tmax,"The Tmax of losartan was prolonged from 0.41 ± 0.12 to 0.52 ± 0.18 h, but the difference was not significant.",Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27327872/),h,0.41,188495,DB00678,Losartan
,27327872,Tmax,"The Tmax of losartan was prolonged from 0.41 ± 0.12 to 0.52 ± 0.18 h, but the difference was not significant.",Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27327872/),h,0.52,188496,DB00678,Losartan
,27327872,Tmax,"However, the Tmax of EXP3174 was decreased significantly (p < 0.05) from 8.14 ± 0.36 to 3.33 ± 0.28 h.",Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27327872/),h,8.14,188497,DB00678,Losartan
,27327872,Tmax,"However, the Tmax of EXP3174 was decreased significantly (p < 0.05) from 8.14 ± 0.36 to 3.33 ± 0.28 h.",Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27327872/),h,3.33,188498,DB00678,Losartan
,27327872,metabolic stability,The metabolic stability of losartan was increased from 37.4 to 59.6 min.,Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27327872/),min,37.4,188499,DB00678,Losartan
,18800456,renal clearance,"For losartan, renal clearance decreased from 50 +/- 19 ml/min in group I to 2.3 +/- 0.9 ml/min in group III (P < 0.05).",The pharmacokinetics of losartan in renal insufficiency. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18800456/),[ml] / [min],50,190729,DB00678,Losartan
,18800456,renal clearance,"For losartan, renal clearance decreased from 50 +/- 19 ml/min in group I to 2.3 +/- 0.9 ml/min in group III (P < 0.05).",The pharmacokinetics of losartan in renal insufficiency. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18800456/),[ml] / [min],2.3,190730,DB00678,Losartan
,18800456,renal clearance,"For E3174, although the renal clearance decreased from 16 +/- 4.1 ml/min in group I to 1.3 +/- 0.8 ml/min in group III (P < 0.05), the area under the plasma concentration curve did not change.",The pharmacokinetics of losartan in renal insufficiency. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18800456/),[ml] / [min],16,190731,DB00678,Losartan
,18800456,renal clearance,"For E3174, although the renal clearance decreased from 16 +/- 4.1 ml/min in group I to 1.3 +/- 0.8 ml/min in group III (P < 0.05), the area under the plasma concentration curve did not change.",The pharmacokinetics of losartan in renal insufficiency. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18800456/),[ml] / [min],1.3,190732,DB00678,Losartan
,8529329,plasma clearance,"In these subjects, the average plasma clearance of losartan was 610 ml/min, and the volume of distribution was 34 L.","Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529329/),[ml] / [min],610,193816,DB00678,Losartan
,8529329,volume of distribution,"In these subjects, the average plasma clearance of losartan was 610 ml/min, and the volume of distribution was 34 L.","Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529329/),l,34,193817,DB00678,Losartan
,8529329,Renal clearance,Renal clearance (70 ml/min) accounted for 12% of plasma clearance.,"Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529329/),[ml] / [min],70,193818,DB00678,Losartan
,8529329,Terminal half-life,Terminal half-life was 2.1 hours.,"Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529329/),h,2.1,193819,DB00678,Losartan
,8529329,plasma clearance,"In contrast, the average plasma clearance of EXP3174 was 47 ml/min, and its volume of distribution was 10 L.","Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529329/),[ml] / [min],47,193820,DB00678,Losartan
,8529329,volume of distribution,"In contrast, the average plasma clearance of EXP3174 was 47 ml/min, and its volume of distribution was 10 L.","Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529329/),l,10,193821,DB00678,Losartan
,8529329,Renal clearance,"Renal clearance was 26 ml/min, which accounted for 55% of plasma clearance; terminal half-life was 6.3 hours.","Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529329/),[ml] / [min],26,193822,DB00678,Losartan
,8529329,terminal half-life,"Renal clearance was 26 ml/min, which accounted for 55% of plasma clearance; terminal half-life was 6.3 hours.","Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529329/),h,6.3,193823,DB00678,Losartan
,8529329,oral bioavailability,The oral bioavailability of losartan tablets was 33%.,"Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529329/),%,33,193824,DB00678,Losartan
,9388040,systemic plasma clearance,The systemic plasma clearance of losartan was 22.1 +/- 4.4 ml/min/kg (mean +/- SEM) and had an apparent volume of distribution at steady state of 0.56 +/- 0.16 L/kg after a 3-mg/kg intravenous dose.,Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9388040/),[ml] / [kg·min],22.1,194412,DB00678,Losartan
,9388040,apparent volume of distribution at steady state,The systemic plasma clearance of losartan was 22.1 +/- 4.4 ml/min/kg (mean +/- SEM) and had an apparent volume of distribution at steady state of 0.56 +/- 0.16 L/kg after a 3-mg/kg intravenous dose.,Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9388040/),[l] / [kg],0.56,194413,DB00678,Losartan
,9388040,elimination half-life,The elimination half-life of losartan was 40 +/- 6 min.,Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9388040/),min,40,194414,DB00678,Losartan
,9388040,plasma clearance,"The plasma clearance of EXP3174 was approximately 50% that of losartan, 11.8 +/- 1.5 ml/min/kg, and had a smaller steady-state apparent volume of distribution, 0.18 +/- 0.04 L/kg.",Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9388040/),[ml] / [kg·min],11.8,194415,DB00678,Losartan
,9388040,steady-state apparent volume of distribution,"The plasma clearance of EXP3174 was approximately 50% that of losartan, 11.8 +/- 1.5 ml/min/kg, and had a smaller steady-state apparent volume of distribution, 0.18 +/- 0.04 L/kg.",Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9388040/),[l] / [kg],0.18,194416,DB00678,Losartan
,9388040,elimination half-life,The elimination half-life for EXP3174 was slightly longer than that of losartan (52 min).,Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9388040/),min,52,194417,DB00678,Losartan
,23118328,C(max),"Sex only affected telmisartan pharmacokinetics, since women showed a higher telmisartan C(max) than men (590.5 ± 75.8 ng/ml versus 282.1 ± 30.8 ng/ml; P ≤ 0.01).","Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),[ng] / [ml],590.5,198029,DB00678,Losartan
,23118328,C(max),"Sex only affected telmisartan pharmacokinetics, since women showed a higher telmisartan C(max) than men (590.5 ± 75.8 ng/ml versus 282.1 ± 30.8 ng/ml; P ≤ 0.01).","Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),[ng] / [ml],282.1,198030,DB00678,Losartan
,23118328,half-life,CYP2C9 variants were associated only with losartan pharmacokinetics: the half-life of losartan was higher in CYP2C9*3 allele carriers (3.1 ± 0.4 hours) than in volunteers with the wild-type genotype (2.3 ± 0.1 hours) (P ≤ 0.05).,"Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),h,3.1,198031,DB00678,Losartan
,23118328,half-life,CYP2C9 variants were associated only with losartan pharmacokinetics: the half-life of losartan was higher in CYP2C9*3 allele carriers (3.1 ± 0.4 hours) than in volunteers with the wild-type genotype (2.3 ± 0.1 hours) (P ≤ 0.05).,"Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),h,2.3,198032,DB00678,Losartan
,23118328,clearance,"CYP2C8 polymorphisms were associated only with valsartan pharmacokinetics, since *2 allele carriers showed faster clearance (1.07 ± 0.57 l/h·kg) than those with the wild-type genotype (0.48 ± 0.72 l/h·kg; P ≤ 0.01) and carriers of the *3 allele (0.35 ± 0.49 l/h·kg; P ≤ 0.001).","Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),[l] / [h·kg],1.07,198033,DB00678,Losartan
,23118328,clearance,"CYP2C8 polymorphisms were associated only with valsartan pharmacokinetics, since *2 allele carriers showed faster clearance (1.07 ± 0.57 l/h·kg) than those with the wild-type genotype (0.48 ± 0.72 l/h·kg; P ≤ 0.01) and carriers of the *3 allele (0.35 ± 0.49 l/h·kg; P ≤ 0.001).","Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),[l] / [h·kg],0.48,198034,DB00678,Losartan
,23118328,clearance,"CYP2C8 polymorphisms were associated only with valsartan pharmacokinetics, since *2 allele carriers showed faster clearance (1.07 ± 0.57 l/h·kg) than those with the wild-type genotype (0.48 ± 0.72 l/h·kg; P ≤ 0.01) and carriers of the *3 allele (0.35 ± 0.49 l/h·kg; P ≤ 0.001).","Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),[l] / [h·kg],0.35,198035,DB00678,Losartan
,17119933,analysis time,"The analysis time for each sample was 4 min, and more than 300 samples could be analyzed in one day by running the system overnight.","Simultaneous determination of losartan, EXP-3174 and hydrochlorothiazide in plasma via fully automated 96-well-format-based solid-phase extraction and liquid chromatography-negative electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17119933/),min,4,203124,DB00678,Losartan
,20636879,50% inhibition concentration,"Myricetin inhibited CYP3A4 and CYP2C9 enzyme activity with a 50% inhibition concentration of 7.8 and 13.5 microm, respectively.","Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20636879/),μm,7.8,208098,DB00678,Losartan
,20636879,50% inhibition concentration,"Myricetin inhibited CYP3A4 and CYP2C9 enzyme activity with a 50% inhibition concentration of 7.8 and 13.5 microm, respectively.","Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20636879/),μm,13.5,208099,DB00678,Losartan
,22264484,IC(50),"Among them, 12a containing thioamido moiety displayed both high in vitro functional antagonism and binding affinity [IC(50)=0.42 and 0.13 nM, respectively] and inhibited strongly in vivo AngII-induced pressor response in pithed rats with an ED(50) of 0.018 mg/kg.",Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22264484/),nM,0.42,212494,DB00678,Losartan
,22264484,IC(50),"Among them, 12a containing thioamido moiety displayed both high in vitro functional antagonism and binding affinity [IC(50)=0.42 and 0.13 nM, respectively] and inhibited strongly in vivo AngII-induced pressor response in pithed rats with an ED(50) of 0.018 mg/kg.",Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22264484/),nM,0.13,212495,DB00678,Losartan
,22264484,ED(50),"Among them, 12a containing thioamido moiety displayed both high in vitro functional antagonism and binding affinity [IC(50)=0.42 and 0.13 nM, respectively] and inhibited strongly in vivo AngII-induced pressor response in pithed rats with an ED(50) of 0.018 mg/kg.",Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22264484/),[mg] / [kg],0.018,212496,DB00678,Losartan
,9650542,plasma clearance,"In these patients, average plasma clearance of losartan was 566 mL/min, volume of distribution at steady-state was 34 L, and terminal plasma half-life was 1.5 hours.",Pharmacokinetics of intravenous and oral losartan in patients with heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9650542/),[ml] / [min],566,212684,DB00678,Losartan
,9650542,volume of distribution at steady-state,"In these patients, average plasma clearance of losartan was 566 mL/min, volume of distribution at steady-state was 34 L, and terminal plasma half-life was 1.5 hours.",Pharmacokinetics of intravenous and oral losartan in patients with heart failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9650542/),l,34,212685,DB00678,Losartan
,9650542,terminal plasma half-life,"In these patients, average plasma clearance of losartan was 566 mL/min, volume of distribution at steady-state was 34 L, and terminal plasma half-life was 1.5 hours.",Pharmacokinetics of intravenous and oral losartan in patients with heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9650542/),h,1.5,212686,DB00678,Losartan
,9650542,bioavailability,Average bioavailability was 36%.,Pharmacokinetics of intravenous and oral losartan in patients with heart failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9650542/),%,36,212687,DB00678,Losartan
,9650542,Terminal plasma half-life,Terminal plasma half-life of EXP3174 after oral administration of losartan was 7.6 hours.,Pharmacokinetics of intravenous and oral losartan in patients with heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9650542/),h,7.6,212688,DB00678,Losartan
,12186413,systemic clearance,The systemic clearance of losartan significantly decreased from 410 +/- 254ml/h/kg in control to 177 +/- 112ml/h/kg in uranyl nitrate-treated rats.,Effect of experimental renal failure on the pharmacokinetics of losartan in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12186413/),[ml] / [h·kg],410,215992,DB00678,Losartan
,12186413,systemic clearance,The systemic clearance of losartan significantly decreased from 410 +/- 254ml/h/kg in control to 177 +/- 112ml/h/kg in uranyl nitrate-treated rats.,Effect of experimental renal failure on the pharmacokinetics of losartan in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12186413/),[ml] / [h·kg],177,215993,DB00678,Losartan
,10984808,clearance,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [h·kg],0.407,223254,DB00678,Losartan
,10984808,volume of distribution,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [kg],4.0,223255,DB00678,Losartan
,10984808,bioavailability,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),%,31,223256,DB00678,Losartan
,10984808,half-life,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),h,10.6,223257,DB00678,Losartan
,17118719,flow rate,"Chromatographic separation was achieved on an ODS-C-18 column (100 mm x 4.6 mm i.d., particle size 5 microm) using isocratic elution (at flow rate 1.25 ml/min).",Liquid chromatographic determination of irbesartan in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118719/),[ml] / [min],1.25,228127,DB00678,Losartan
,17118719,total time,"The peak was detected using a fluorescence detector set at Ex 259 nm and Em 385 nm, and the total time for a chromatographic separation was approximately 13 min.",Liquid chromatographic determination of irbesartan in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118719/),min,13,228128,DB00678,Losartan
,17118719,recoveries,Mean recoveries were 73.3-77.1% with coefficients of variation of 3.7-6.3%.,Liquid chromatographic determination of irbesartan in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118719/),%,73.3-77.1,228129,DB00678,Losartan
>,17118719,Stability,"Stability of irbesartan in plasma was >89%, with no evidence of degradation during sample processing and 60 days storage in a deep freezer at -70 degrees C.",Liquid chromatographic determination of irbesartan in human plasma. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17118719/),%,89,228130,DB00678,Losartan
,23781473,flow rate,"The reconstituted samples were chromatographed on a C18 column by using an 85:15, v/v mixture of methanol and 0.1% v/v formic acid as the mobile phase at a flow rate of 1.0 mL/min.","Simultaneous determination of losartan, losartan acid and amlodipine in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23781473/),[ml] / [min],1.0,230210,DB00678,Losartan
,23781473,run time,A run time of 2.5 min for each sample made it possible to analyze more than 300 plasma samples per day.,"Simultaneous determination of losartan, losartan acid and amlodipine in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23781473/),min,2.5,230211,DB00678,Losartan
,26397395,IC₅₀,"The screening of decreased blood pressure in spontaneous hypertensive rats displayed that compound 8S (IC₅₀ = 5.0 nM) was equipotent with Losartan, whereas compounds 13R (IC₅₀ = 7.3 nM), 14R (IC₅₀ = 6.3 nM), and 14S (IC₅₀ = 3.5 nM) were slightly ahead of Losartan, and the most significant activity was demonstrated by compound 8R (IC₅₀ = 1.1 nM).","Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26397395/),nM,5.0,231312,DB00678,Losartan
,26397395,IC₅₀,"The screening of decreased blood pressure in spontaneous hypertensive rats displayed that compound 8S (IC₅₀ = 5.0 nM) was equipotent with Losartan, whereas compounds 13R (IC₅₀ = 7.3 nM), 14R (IC₅₀ = 6.3 nM), and 14S (IC₅₀ = 3.5 nM) were slightly ahead of Losartan, and the most significant activity was demonstrated by compound 8R (IC₅₀ = 1.1 nM).","Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26397395/),nM,7.3,231313,DB00678,Losartan
,26397395,IC₅₀,"The screening of decreased blood pressure in spontaneous hypertensive rats displayed that compound 8S (IC₅₀ = 5.0 nM) was equipotent with Losartan, whereas compounds 13R (IC₅₀ = 7.3 nM), 14R (IC₅₀ = 6.3 nM), and 14S (IC₅₀ = 3.5 nM) were slightly ahead of Losartan, and the most significant activity was demonstrated by compound 8R (IC₅₀ = 1.1 nM).","Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26397395/),nM,6.3,231314,DB00678,Losartan
,26397395,IC₅₀,"The screening of decreased blood pressure in spontaneous hypertensive rats displayed that compound 8S (IC₅₀ = 5.0 nM) was equipotent with Losartan, whereas compounds 13R (IC₅₀ = 7.3 nM), 14R (IC₅₀ = 6.3 nM), and 14S (IC₅₀ = 3.5 nM) were slightly ahead of Losartan, and the most significant activity was demonstrated by compound 8R (IC₅₀ = 1.1 nM).","Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26397395/),nM,3.5,231315,DB00678,Losartan
,26397395,IC₅₀,"The screening of decreased blood pressure in spontaneous hypertensive rats displayed that compound 8S (IC₅₀ = 5.0 nM) was equipotent with Losartan, whereas compounds 13R (IC₅₀ = 7.3 nM), 14R (IC₅₀ = 6.3 nM), and 14S (IC₅₀ = 3.5 nM) were slightly ahead of Losartan, and the most significant activity was demonstrated by compound 8R (IC₅₀ = 1.1 nM).","Discovery of novel, potent and low-toxicity angiotensin II receptor type 1 (AT1) blockers: Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazoles with a chiral center. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26397395/),nM,1.1,231316,DB00678,Losartan
,8161716,absolute oral bioavailability,"In rats, the absolute oral bioavailability and half-life averaged 8.0% and 3.5 h, respectively, after the sodium bicarbonate solution and 7.6% and 3.6 h, respectively, after the methyl cellulose suspension.","The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161716/),%,8.0,235763,DB00678,Losartan
,8161716,absolute oral bioavailability,"In rats, the absolute oral bioavailability and half-life averaged 8.0% and 3.5 h, respectively, after the sodium bicarbonate solution and 7.6% and 3.6 h, respectively, after the methyl cellulose suspension.","The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161716/),%,7.6,235764,DB00678,Losartan
,8161716,half-life,"In rats, the absolute oral bioavailability and half-life averaged 8.0% and 3.5 h, respectively, after the sodium bicarbonate solution and 7.6% and 3.6 h, respectively, after the methyl cellulose suspension.","The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161716/),h,3.5,235765,DB00678,Losartan
,8161716,half-life,"In rats, the absolute oral bioavailability and half-life averaged 8.0% and 3.5 h, respectively, after the sodium bicarbonate solution and 7.6% and 3.6 h, respectively, after the methyl cellulose suspension.","The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161716/),h,3.6,235766,DB00678,Losartan
,8161716,absolute oral bioavailability,"In dogs, the absolute oral bioavailability averaged 13.4% after the sodium bicarbonate solution and 11.9% after hard gelatin capsules containing the neat powder.","The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161716/),%,13.4,235767,DB00678,Losartan
,8161716,absolute oral bioavailability,"In dogs, the absolute oral bioavailability averaged 13.4% after the sodium bicarbonate solution and 11.9% after hard gelatin capsules containing the neat powder.","The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161716/),%,11.9,235768,DB00678,Losartan
greater,8161716,recovery,"HPLC analyses with UV and radiochemical flow detection showed that recovery of DuP 532 was greater than 99%, suggesting that there was little if any metabolism by liver microsomal enzymes.","The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161716/),%,99,235769,DB00678,Losartan
,29768080,Cmax,"3. The results showed that when the rats were pretreated with quercetin, the Cmax (2.16 ± 0.40 vs. 1.33 ± 0.21 mg/L) and the AUC(0-t) (13.89 ± 1.22 vs.",Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29768080/),[mg] / [l],2.16,244214,DB00678,Losartan
,29768080,Cmax,"3. The results showed that when the rats were pretreated with quercetin, the Cmax (2.16 ± 0.40 vs. 1.33 ± 0.21 mg/L) and the AUC(0-t) (13.89 ± 1.22 vs.",Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29768080/),[mg] / [l],1.33,244215,DB00678,Losartan
,29768080,AUC(0-t),"3. The results showed that when the rats were pretreated with quercetin, the Cmax (2.16 ± 0.40 vs. 1.33 ± 0.21 mg/L) and the AUC(0-t) (13.89 ± 1.22 vs.",Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29768080/),,13.89,244216,DB00678,Losartan
,29768080,Cmax,"7.34 ± 0.75 mg·h/L) of losartan increased significantly (p < .05), and while the Cmax (0.76 ± 0.09 vs. 1.14 ± 0.18 mg/L) of EXP3174 decreased significantly compared to the control (p < .05).",Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29768080/),[mg] / [l],0.76,244217,DB00678,Losartan
,29768080,Cmax,"7.34 ± 0.75 mg·h/L) of losartan increased significantly (p < .05), and while the Cmax (0.76 ± 0.09 vs. 1.14 ± 0.18 mg/L) of EXP3174 decreased significantly compared to the control (p < .05).",Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29768080/),[mg] / [l],1.14,244218,DB00678,Losartan
,29768080,t1/2,The t1/2 of losartan was prolonged from 3.27 ± 0.45 h to 4.74 ± 0.51 h (p < .05).,Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29768080/),h,3.27,244219,DB00678,Losartan
,29768080,t1/2,The t1/2 of losartan was prolonged from 3.27 ± 0.45 h to 4.74 ± 0.51 h (p < .05).,Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29768080/),h,4.74,244220,DB00678,Losartan
,18399713,"dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],375.5,250691,DB00678,Losartan
,18399713,"dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],548.5,250692,DB00678,Losartan
,18399713,"AUC(24,ss)/D","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],352.3,250693,DB00678,Losartan
,18399713,"AUC(24,ss)/D","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],487.6,250694,DB00678,Losartan
,18399713,"AUC(24,ss)/D","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],359.5,250695,DB00678,Losartan
,18399713,"AUC(24,ss)/D","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],547.3,250696,DB00678,Losartan
,7641363,area under the plasma active renin versus time curve (0 to 24 hours),"After combined losartan-captopril administration, the area under the plasma active renin versus time curve (0 to 24 hours) was significantly increased when compared with either losartan or captopril alone (6404 +/- 2961 pg.h.mL-1 versus 3105 +/- 1461 pg.h.mL-1 versus 2092 +/- 867 pg.h.mL-1, respectively, P < .05).",Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7641363/),[h·pg] / [ml],6404,255254,DB00678,Losartan
,7641363,area under the plasma active renin versus time curve (0 to 24 hours),"After combined losartan-captopril administration, the area under the plasma active renin versus time curve (0 to 24 hours) was significantly increased when compared with either losartan or captopril alone (6404 +/- 2961 pg.h.mL-1 versus 3105 +/- 1461 pg.h.mL-1 versus 2092 +/- 867 pg.h.mL-1, respectively, P < .05).",Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7641363/),[h·pg] / [ml],3105,255255,DB00678,Losartan
,7641363,area under the plasma active renin versus time curve (0 to 24 hours),"After combined losartan-captopril administration, the area under the plasma active renin versus time curve (0 to 24 hours) was significantly increased when compared with either losartan or captopril alone (6404 +/- 2961 pg.h.mL-1 versus 3105 +/- 1461 pg.h.mL-1 versus 2092 +/- 867 pg.h.mL-1, respectively, P < .05).",Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7641363/),[h·pg] / [ml],2092,255256,DB00678,Losartan
,21870106,T(max),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,3.03,259984,DB00678,Losartan
,21870106,T(1/2),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,3.66,259985,DB00678,Losartan
,21870106,T(1/2),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,0.66,259986,DB00678,Losartan
,21870106,T(1/2),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,0.99,259987,DB00678,Losartan
,16029066,terminal half-life,E 3174 is 10- to 40-fold more potent than its parent compound and its estimated terminal half-life ranges from 6 to 9 hours.,Clinical pharmacokinetics of losartan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029066/),h,6 to 9,263266,DB00678,Losartan
,8471405,"terminal half-lives (t1/2,z)","3. Plasma concentrations of losartan were proportional to dose over the range of 25 to 200 mg and the terminal half-lives (t1/2,z) ranged from 1.5 to 2.5 h.","Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8471405/),h,1.5 to 2.5,263866,DB00678,Losartan
,8966199,Elimination half-life,"Elimination half-life, systemic clearance, and apparent volume of distribution of EXP3174 at a dose of 10 mg/kg i.v. were 2.9 h, 1.8 ml/min/kg, and 0.25 l/kg, respectively.","Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8966199/),h,2.9,265902,DB00678,Losartan
,8966199,systemic clearance,"Elimination half-life, systemic clearance, and apparent volume of distribution of EXP3174 at a dose of 10 mg/kg i.v. were 2.9 h, 1.8 ml/min/kg, and 0.25 l/kg, respectively.","Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8966199/),[ml] / [kg·min],1.8,265903,DB00678,Losartan
,8966199,apparent volume of distribution,"Elimination half-life, systemic clearance, and apparent volume of distribution of EXP3174 at a dose of 10 mg/kg i.v. were 2.9 h, 1.8 ml/min/kg, and 0.25 l/kg, respectively.","Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8966199/),[l] / [kg],0.25,265904,DB00678,Losartan
,8966199,IC50,Inhibition of the angiotensin II pressor response correlated with the log of the steady state plasma EXP3174 concentration in a sigmoidal fashion with an IC50 of about 200 ng/ml.,"Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8966199/),[ng] / [ml],200,265905,DB00678,Losartan
,8966199,IC50,"When corrected for plasma protein binding, the IC50 (free) for EXP3174 was 0.4 ng/ml (0.9 nmol/l).","Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8966199/),[ng] / [ml],0.4,265906,DB00678,Losartan
,8966199,IC50,"When corrected for plasma protein binding, the IC50 (free) for EXP3174 was 0.4 ng/ml (0.9 nmol/l).","Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8966199/),[nM] / [l],0.9,265907,DB00678,Losartan
,8751032,maximum mean increases,"The increase in plasma renin activity following losartan was not affected by cimetidine (maximum mean increases 12.6 and 12.1 ng Ang I.ml-1.h-1 without and with cimetidine, respectively).","Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751032/),[ang·i·ng] / [h·ml],12.6,270809,DB00678,Losartan
,8751032,maximum mean increases,"The increase in plasma renin activity following losartan was not affected by cimetidine (maximum mean increases 12.6 and 12.1 ng Ang I.ml-1.h-1 without and with cimetidine, respectively).","Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751032/),[ang·i·ng] / [h·ml],12.1,270810,DB00678,Losartan
,12761811,bioavailability,"Furthermore, a high bioavailability was found for the efflux transporter substrates talinolol (81%) and losartan (92%), which provides functional evidence for a quantitatively less important role for efflux transporters, such as P-glycoprotein, in limiting the absorption of these drugs from the rat lung.",Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761811/),%,81,273407,DB00678,Losartan
,12761811,bioavailability,"Furthermore, a high bioavailability was found for the efflux transporter substrates talinolol (81%) and losartan (92%), which provides functional evidence for a quantitatively less important role for efflux transporters, such as P-glycoprotein, in limiting the absorption of these drugs from the rat lung.",Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12761811/),%,92,273408,DB00678,Losartan
,32538215,t max,"Pharmacokinetic studies revealed that calculated t max was 9.72 ± 2.22 h from the optimized sustained release pellets compared to 2.11 ± 0.49 h in case of Cozaar® immediate release tablet, indicating a slower release of the LP from pellets.",Losartan potassium sustained release pellets with improved in vitro and in vivo performance. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32538215/),h,9.72,273512,DB00678,Losartan
,32538215,t max,"Pharmacokinetic studies revealed that calculated t max was 9.72 ± 2.22 h from the optimized sustained release pellets compared to 2.11 ± 0.49 h in case of Cozaar® immediate release tablet, indicating a slower release of the LP from pellets.",Losartan potassium sustained release pellets with improved in vitro and in vivo performance. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32538215/),h,2.11,273513,DB00678,Losartan
